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Introduction {#sec005}
============

Globally, the burden of diabetes is increasing. The number of adults living with diabetes is expected to increase from 429 million to 629 million by the year 2045---which is almost a 50% increase in the number of the affected population \[[@pone.0237571.ref001]\]. Furthermore, in low and middle-income countries, the burden of diabetes is higher among the younger population, including women in the reproductive age group \[[@pone.0237571.ref002]\]. If the current situation remains unabated, a substantial increase in high risk pregnancies complicated with pregestational diabetes will create major health care problems in low income countries due to the higher mortality and morbidity associated with pregestational diabetes compared to non-diabetic pregnancies.

Hyperglycemia in early pregnancy increases the risk of congenital abnormalities by ninefold compared to the normoglycemic population \[[@pone.0237571.ref003]\]. There is a fivefold increase in the rate of cardiovascular abnormalities and a twofold increase in the rate of neural tube and urinary tract defects in infants of mothers with diabetes compared to the background population \[[@pone.0237571.ref004], [@pone.0237571.ref005]\]. Congenital defects and preterm births \[[@pone.0237571.ref006]\] were the main contributors to the high rate of perinatal mortality observed in pregnancies complicated by maternal pregestational diabetes \[[@pone.0237571.ref007], [@pone.0237571.ref008]\].

Many of the serious complications of pregestational diabetes can be averted by implementing preconception care (PCC) \[[@pone.0237571.ref009]\]. Education about the interaction between diabetes and pregnancy, family planning combined with diabetes self-management skills can achieve optimum glycemic control during early pregnancy, which can reduce rates of congenital abnormalities and perinatal mortality \[[@pone.0237571.ref010]\].

Other essential elements of PCC include; folic acid supplementation \[[@pone.0237571.ref011]\], lifestyle modification (weight reduction, smoking cessation), multidisciplinary medical care (endocrinologist, obstetrician, dietitian and midwives specialized in diabetes), and substituting teratogenic medications for safer ones \[[@pone.0237571.ref012]\].

Despite the proven clinical value and cost-effectiveness of PCC \[[@pone.0237571.ref013]\], there is low uptake of the service in some communities and lack of it in others. Most pregnancies are unplanned, which makes PCC unfeasible for almost 40% of women with pregestational diabetes \[[@pone.0237571.ref014]\]. In addition, the deprived socioeconomic status in low income countries plays a part in access and utilization of PCC \[[@pone.0237571.ref015]\], which puts a considerable proportion of women with diabetes at risk of adverse pregnancy outcomes.

Since the publication of our last systematic review on the effectiveness of PCC in improving maternal and perinatal outcomes, many studies have been published to investigate different interventions and outcomes of PCC \[[@pone.0237571.ref009], [@pone.0237571.ref016]\]. Additionally, with the increased recognition of the importance of evaluation of the body of evidence a grading tool, Grading of Recommendations Assessment, Development and Evaluation (GRADE), has been introduced to facilitate evidence-based decision making for interventions in clinical medicine and health policy \[[@pone.0237571.ref017]\].

The objectives of this systematic review are to assess the effectiveness of PCC comprehensively in improving maternal and perinatal outcomes and to evaluate the grade of the body of evidence for each outcome.

Methods {#sec006}
=======

Search methods {#sec007}
--------------

A structured literature search was undertaken to review all the literature published up to March 2019. The search strategy was developed with the help of library and information retrieval specialist. We searched the following databases: MEDLINE, EMBASE, WEB OF SCIENCE, CINHAL and Google Scholar; (For full search strategy, see **[S1 File](#pone.0237571.s002){ref-type="supplementary-material"}).** Additionally, bibliographies of retrieved articles were manually searched for potentially relevant papers. No language or date restrictions were applied in the search.

Study selection {#sec008}
---------------

The following criteria were applied for eligibility:

-   Randomized and quasi-randomized controlled trials, cluster-randomized trials, and observational (cohort, cross-sectional and case control) studies were eligible for inclusion.

-   Studies and trials which compared the frequency of maternal and perinatal adverse outcomes in women with diabetes who received PCC with those who did not receive PCC.

-   Women of reproductive age with pregestational diabetes type 1 or type 2 diabetes mellitus who were not pregnant at the time of intervention.

-   PCC interventions including (i.e. either as sole intervention or in combination): Glycemic control by insulin and/or diet and/or oral hypoglycemic drugs.Women counselling and/or education about diabetes complications during pregnancy, the importance of glycemic control and self-monitoring of blood glucose level.Preconception screening and treatment of complications of diabetesThe use of contraception until optimization of glycemic control is achievedIntake of multivitamin or folic acid in the preconception period.Physical exercise and/or weight control.

-   Studies reporting maternal and neonatal outcomes as follows:

Maternal outcomes:

-   Hemoglobin A1c (HbA1c) level in the first trimester of pregnancy

-   Gestation age (GA) at the time of the first visit to antenatal care clinic (booking visit)

-   Miscarriage or termination of pregnancy due to congenital abnormalities

-   Induction of labor due to maternal complications of diabetes

-   Delivery by cesarean section (CS) or instrumental delivery

-   Maternal hypoglycemia in the first trimester

Neonatal outcomes:

-   Preterm delivery

-   Congenital malformations related to maternal diabetes

-   Perinatal mortality (stillbirth and neonatal death)

-   Birth trauma

-   Admission to neonatal intensive care unit (NICU)

-   Respiratory distress syndrome (RDS)

-   Macrosomia (birth weight ≥ 4 kg for term infants or large for gestational age (LGA)birth weight ≥ 90th percentile for the gestation age)

-   Small for gestational age (SGA) (birth weight below the 10th percentile for the gestational age)

-   Shoulder dystocia

-   Neonatal hypoglycemia

Study identification {#sec009}
--------------------

We screened titles and abstracts of all the potential studies identified as a result of the search by two reviewers independently. Disagreements were resolved through discussion or after consultation with a third reviewer when needed.

Articles with the criteria below were excluded from the review:

-   Did not contain a complete description of the study or study population

-   Did not report original data (commentary, review or editorial) or reports of conference proceedings or abstracts when complete data could not be retrieved from the authors

-   Participants were not women with pregestational diabetes or were pregnant at the time of intervention

-   Did not assess impact of a PCC intervention

-   Did not include comparatives arms.

Then the full-text papers were retrieved, and potentially relevant studies were assessed independently by two authors for eligibility by application of the inclusion/exclusion criteria. The review was registered in PROSPERO (registration number CRD42019114336) \[[@pone.0237571.ref018]\].

Data extraction {#sec010}
---------------

The data were subsequently extracted from included studies by two reviewers using a purposefully designed data extraction form. The reviewers were not masked to the articles' authors, journals, or institutions. The data extracted were: country and year of publication, settings, study design, study duration, study population details of intervention/s and control, and outcomes. When information regarding any of the above was unclear, the authors were contacted to provide the missing details. Any disagreement on value or type of data extracted between reviewers was resolved through discussion or by consulting a third reviewer.

Quality assessment {#sec011}
------------------

### Assessment of risk of bias {#sec012}

Two reviewers independently assessed the risk of bias for each cohort/ case control study using The Newcastle-Ottawa Scale (NOS) \[[@pone.0237571.ref019]\]. The criteria assessed for cohort studies were: participants' selection, comparability of groups and assessment of outcome. While participants' selection, comparability of groups, and exposure criteria were used to assess the case-control studies. The maximum number of stars awarded for any study were nine: four stars awarded for selection of participants (exposed and non- exposed), ascertainment of exposure and temporal relation between exposure and outcome, two stars were awarded for comparability, if analysis controlled for confounding factors, and three stars were awarded for outcomes if the length of follow up was adequate, with no attrition bias, and if the outcomes were assessed independent of exposure. Studies at "high risk of bias" score less than six stars or scores no stars in comparability domain irrespective of the number of stars scored. Any difference in grading of studies was reconciled by discussion or by involving a third reviewer. For randomized controlled trials, we used the Cochrane tool for bias assessment \[[@pone.0237571.ref020]\].

### Overall risk of bias for outcomes {#sec013}

We made explicit judgements about whether studies included in the meta-analysis of each of the main outcomes, were at high risk of bias according to the NOS criteria. We assessed the likely magnitude and direction of the bias and whether the likelihood of having an impact on the findings was of any significance.

### Publication bias {#sec014}

We assessed the presence of publication bias using Funnel Plots of effect size against standard error for each meta-analysis that included ten or more studies according to Cochrane collaboration methodology. Three analyses were eligible for publication bias assessment including: the effect of PCC on congenital malformations (25 studies), HbA1C (24 studies) and perinatal mortality (ten studies). The vertical axis of the plot represents the standard error, while the horizontal axis represents the logarithmic scale of risk ratio for dichotomous variables in case of congenital malformations and perinatal mortality. In the case of continuous variables, as in HbA1c, the horizontal axis represents the standardized mean difference. Furthermore, we assessed selective reporting in all outcomes \[[@pone.0237571.ref020]\].

### Assessment of the quality of the evidence {#sec015}

The overall quality and strength of evidence for the main outcomes were assessed using the GRADE approach \[[@pone.0237571.ref021]\]. We created a \'Summary of findings\' tables for the main outcomes of the review. The body of evidence is downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations depending on assessments of risk of bias, indirectness of evidence, inconsistency, imprecision of effect estimates or potential publication bias. Subsequently, the quality of evidence was graded as 'high', 'moderate', 'low' or 'very low' certainty. Evidence derived from observational studies receive an initial grade of 'low', however, we upgraded the quality of evidence when there was a large magnitude of effect (RR\>2 or RR\<0.5, in the absence of plausible confounders) \[[@pone.0237571.ref021]\]. We downgraded scores for risk of bias (weight of studies show risk of bias as assessed by low NOS \<6), inconsistency (unexplained heterogeneity), indirectness of evidence (presence of factors that limit the generalizability of the results), imprecision in the pooled risk estimate (the 95% CI for risk estimates are wide or cross a minimally important difference of 10% for benefit or harm (RR 0.9--1.1)), and publication bias (evidence of small-study effects) \[[@pone.0237571.ref021]\]. We used the GRADEpro tool in order to create the \'Summary of findings\' tables \[[@pone.0237571.ref022]\]. We assessed the quality of the body of evidence relating to the following outcomes for the main comparison, PCC versus no PCC; 1) Congenital malformations 2) HbA1c in the first trimester of pregnancy 3) Perinatal mortality 4) Preterm delivery 5) Maternal hypoglycemia 6) Gestational age at booking for antenatal care.

We produced a summary of the intervention effect using the GRADE approach, a measure of quality for each of the above outcomes.

### Data synthesis {#sec016}

A statistical analysis using RevMan 5 software (RevMan 2014) was carried out \[[@pone.0237571.ref023]\]. We used the fixed-effect model to conduct meta-analyses. The pooled statistics was reported as either relative risk (RR) for categorical variables, or mean difference (MD) for continuous variables in the comparison between the intervention and control groups with 95% confidence intervals (CI). Heterogeneity was quantified in each meta-analysis using the Tau^2^, I^2^ and Chi^2^ statistics \[[@pone.0237571.ref024]\]. We regarded heterogeneity as substantial if I^2^ was ≥ 50% and either Tau^2^ was greater than zero, or there was a low *p* value (less than 0.10) in the Chi^2^ test for heterogeneity.

We conducted sensitivity analyses by excluding studies with high risk of bias from the metanalysis for the main review outcomes. We conducted sensitivity analysis for two maternal outcomes which are gestation age at the first antenatal visit and first trimester HBA1c level, in addition to five neonatal outcomes, including: congenital malformations, preterm delivery, perinatal mortality, SGA, and admission to NICU.

### Differences between the protocol and the review {#sec017}

The authors decided to utilize the modified version of NOS proposed by the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services \[[@pone.0237571.ref025], [@pone.0237571.ref026]\] as it was more rigorous, robust, and user-friendly than the original version proposed by the University of Ottawa \[[@pone.0237571.ref019]\].

We conducted additional sensitivity analysis by excluding studies with high risk of bias from certain outcomes

Results {#sec018}
=======

Literature search {#sec019}
-----------------

Our initial search identified 8500 potentially relevant citations of which 76 full text articles were reviewed ([Fig 1](#pone.0237571.g001){ref-type="fig"}). We identified 40 reports of 36 studies for inclusion in the analysis. Among these reports, three articles described the same cohort study with two interim \[[@pone.0237571.ref027], [@pone.0237571.ref028]\] and one final report \[[@pone.0237571.ref029]\], one study reported the outcomes of the same cohort in two articles \[[@pone.0237571.ref030], [@pone.0237571.ref031]\] and two articles reported the outcomes of one cohort with one interim \[[@pone.0237571.ref032]\] and one final report \[[@pone.0237571.ref033]\].

![Process of selection of the studies for the systematic review (PRISMA flow chart).](pone.0237571.g001){#pone.0237571.g001}

Thirty-six studies were excluded because: they did not meet the inclusion criteria, or were review articles, data were not extractable in three studies, and one report was excluded because of co-intervention applied at national level \[[@pone.0237571.ref034]\].

Study characteristics {#sec020}
---------------------

### Participants {#sec021}

The main characteristics of included studies are summarized in Tables [1](#pone.0237571.t001){ref-type="table"}--[3](#pone.0237571.t003){ref-type="table"}. There were 36 included studies conducted through March 2019, all of which were conducted in high income countries \[[@pone.0237571.ref035]\]. Of the included studies 18 were prospective cohort studies \[[@pone.0237571.ref031], [@pone.0237571.ref036]--[@pone.0237571.ref052]\], 16 were retrospective cohort studies \[[@pone.0237571.ref029], [@pone.0237571.ref032], [@pone.0237571.ref033], [@pone.0237571.ref049], [@pone.0237571.ref053]--[@pone.0237571.ref065]\], one was a trial \[[@pone.0237571.ref066]\], and one was a case control study \[[@pone.0237571.ref067]\]. The number of participants of cohort studies were 8199 women, among whom 3213 received PCC followed by antenatal care, whilst 4986 only received antenatal care. There were 24 participants in the case control study \[[@pone.0237571.ref067]\] and 180 pregnancies in the trial \[[@pone.0237571.ref066]\]. Most of studies did not report the differences in the outcomes among type 1 versus type 2 diabetes, subsequently, we could not conduct the analysis separately for each type of diabetes.

10.1371/journal.pone.0237571.t001

###### Characteristics of included cohort studies.

![](pone.0237571.t001){#pone.0237571.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Serial No.   Study ID                                                           Participants                                                                                    Intervention                                                                                                                                                                                                                                                                          Outcomes
  ------------ ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  **1**        **Boulot** (2003)\                                                 **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               France \[[@pone.0237571.ref045]\]                                  **175** women with (DM-I and DM-II)\                                                            • Educational delivered by health care of professionals,\                                                                                                                                                                                                                             **Perinatal mortality:** (3/175)\
                                                                                  **NO-PCC:**\                                                                                    • Assessment of diabetes complications,\                                                                                                                                                                                                                                              **Congenital malformations:** (2/175)\
                                                                                  **260** women with (DM-I and DM-II)                                                             • Advice regarding blood glucose optimization,\                                                                                                                                                                                                                                       **NO-PCC:**\
                                                                                                                                                                                  • Dietary modification,\                                                                                                                                                                                                                                                              **Perinatal mortality:** (16/260)\
                                                                                                                                                                                  • Self-monitoring of blood glucose levels, and insulin therapy.                                                                                                                                                                                                                       **Congenital malformations:** (16/260)

  **2**        **Cousins** (1991)\                                                **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               USA\[[@pone.0237571.ref037]\]                                      **27** women with (DM-I and DM-II)\                                                             • A multidisciplinary team approach to care (physicians, Diabetes educators, dietitians and social workers),\                                                                                                                                                                         **Congenital malformations:** (0/27)\
                                                                                  **NO-PCC:**\                                                                                    • Comprehensive education,\                                                                                                                                                                                                                                                           **NO-PCC:**\
                                                                                  **347** women with (DM-I and DM-II) received care after conception                              • Active self- management (e.g. self-glucose monitoring, home testing for ketone- urea, insulin injection techniques),\                                                                                                                                                               **Congenital malformations:** (23/347)
                                                                                                                                                                                  • Routine maternal care elements and laboratory tests,\                                                                                                                                                                                                                               
                                                                                                                                                                                  • History and physical examination.                                                                                                                                                                                                                                                   

  **3**        **Damm** (1989) Denmark\[[@pone.0237571.ref036]\]                  **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **197** women with (DM-I)\                                                                      • Optimization of diabetic control at the time of conception and nidation and during the first trimester,\                                                                                                                                                                            **First trimester HbA1c:** 7.1 ± SD 1.2 (N = 64)\
                                                                                  **NO-PCC**:\                                                                                    • Pregnancy planning and contraceptive guidance.                                                                                                                                                                                                                                      **Congenital malformations:** (2/197)\
                                                                                  **61** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                              **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 7.3 ± SD 1.5 (N = 21)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (5/61)

  **4**        **Dicker** (1988)\                                                 **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               Israel\[[@pone.0237571.ref055]\]                                   **59** women with (DM-I)\                                                                       • Insulin and dietary glycemic control,\                                                                                                                                                                                                                                              **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c:** 7.39 ± SD 0.33 (N = 59)\
                                                                                  **NO-PCC**:\                                                                                    • Advice on contraception,\                                                                                                                                                                                                                                                           **Miscarriage:** (5/59)\
                                                                                  **35** women with (DM-I)                                                                        • Screening for diabetes complications.                                                                                                                                                                                                                                               **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c:** 10.49 ± SD 0.48 (N = 35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (10/35)

  **5**        **Egan** (2016)\                                                   **PCC**:\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               Ireland \[[@pone.0237571.ref050]\]                                 **149** women with (DM-I and DM-II)\                                                            • Patient education,\                                                                                                                                                                                                                                                                 **First trimester HbA1c:** 6.8 ± SD 1.2 (N = 149)\
                                                                                  **NO-PCC**:\                                                                                    • Full medication review,\                                                                                                                                                                                                                                                            **CS delivery:** (85/149)\
                                                                                  **265** women with (DM-I and DM-II)                                                             • Assessment and treatment of diabetes complications and thyroid status.\                                                                                                                                                                                                             **Congenital malformations:** (1/149)\
                                                                                                                                                                                  • Folic acid supplement,\                                                                                                                                                                                                                                                             **Miscarriage:** (25/149)\
                                                                                                                                                                                  • Intensive glucose monitoring with a target HbA1c of less than 6.1%,\                                                                                                                                                                                                                **Instrumental delivery:** (11/149)\
                                                                                                                                                                                  • Dietary advice and Pregnancy planning.                                                                                                                                                                                                                                              **Maternal hypertension:** (25/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preeclampsia:** (13/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (17/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Serious adverse outcome: (**3/149**)**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Shoulder dystocia:** (0/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **[\#](#t001fn004){ref-type="table-fn"}Perinatal mortality:** (2/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **[^\~^](#t001fn003){ref-type="table-fn"}LGA:** (49/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA:** (5/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Excessive GWG:** (61/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal hypoglycemia:** (15/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NICU admission:** (54/149)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 7.7 ± SD 1.8 (N = 265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS delivery:** (142/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (12/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (36/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Instrumental delivery:** (26/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Maternal hypertension:** (54/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preeclampsia:** (28/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (47/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Serious adverse outcome:** (24/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Shoulder dystocia:** (6/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **[\#](#t001fn004){ref-type="table-fn"}Perinatal mortality:** (8/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **[^\~^](#t001fn003){ref-type="table-fn"}LGA:** (75/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA:** (20/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Excessive GWG:** (80/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal hypoglycemia:** (22/265)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NICU admission:** (137/265)

  **6**        **Cyganek** (2010) Poland \[[@pone.0237571.ref058]\]               **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **116** women with (DM-I)\                                                                      • Intensive diabetes management.                                                                                                                                                                                                                                                      **Preterm delivery:** (22/116)\
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          **CS delivery:** (73/116)\
                                                                                  **153** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                             **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (41/153)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (116/153)

  **7**        **Cyganek** (2016) Poland \[[@pone.0237571.ref064]\]               **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **210** women with (DM-I)\                                                                      • Glycemic control,\                                                                                                                                                                                                                                                                  **First trimester HbA1c:** 6.4 ± SD 1.1 (N = 210)\
                                                                                  **NO-PCC**:\                                                                                    • Assessment of diabetes complications.                                                                                                                                                                                                                                               **NO-PCC:**\
                                                                                  **313** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                             **First trimester HbA1c:** 7.5 ± SD 1.5 (N = 313)

  **8**        **Dunne** (1999)\                                                  **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               United Kingdom\[[@pone.0237571.ref056]\]                           **12** women with (DM-I)\                                                                       • Glycemic control,\                                                                                                                                                                                                                                                                  **First trimester HbA1c:** 7.9 ± SD 1.4 (N = 12)\
                                                                                  **NO-PCC**:\                                                                                    • Assessment of diabetes complications.                                                                                                                                                                                                                                               **Preterm delivery:** (5/12)\
                                                                                  **35** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                              **CS delivery:** (9/12)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NICU admission:** (2/12)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA:** (4/12)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA:** (0/12)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (0/12)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (0/12)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 9.6 ± SD 2.4 (N = 35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (15/35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (26/35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NICU admission: (**12/35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA:** (14/35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA:** (3/35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (2/35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (0/35)

  **9**        **Evers** (2004) Netherland \[[@pone.0237571.ref047]\]             **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **27**1 women with (DM-I)\                                                                      • Planned pregnancy,\                                                                                                                                                                                                                                                                 **First trimester HbA1c:** 6.4 ± SD 0.9\
                                                                                  **NO-PCC**:\                                                                                    • Folic acid supplementation,\                                                                                                                                                                                                                                                        (N = 271)\
                                                                                  **52** women with (DM-I)                                                                        • Glycemic control.                                                                                                                                                                                                                                                                   **Congenital malformations:** (11/271)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 7.0 ± SD 1.4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (N = 52)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (6/ 52)

  **10**       **Fuhrmann** (1986, 1983 & 1984)\                                  **PCC**:\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               Germany\[[@pone.0237571.ref027]--[@pone.0237571.ref029]\]          **185** women with (DM-I)\                                                                      • Hospital based glycemic control,\                                                                                                                                                                                                                                                   **Congenital malformations:** (2/185)\
                                                                                  **NO-PCC**:\                                                                                    • Glucose self-monitoring.                                                                                                                                                                                                                                                            **NO-PCC:**\
                                                                                  **437** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                             **Congenital malformations:** (31/437)

  **11**       **Galindo** (2006) Spain\[[@pone.0237571.ref048]\]                 **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **15** women with (DM-I and DM-II)\                                                             • Education,\                                                                                                                                                                                                                                                                         **First trimester HbA1c:** 5.8 ± SD 0.98\
                                                                                  **NO-PCC**:\                                                                                    • Glycemic control,\                                                                                                                                                                                                                                                                  (N = 15)\
                                                                                  **111** women with (DM-I and DM-II)                                                             • Self-monitoring of blood glucose.                                                                                                                                                                                                                                                   **Congenital malformations:** (3/15)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 6.6 ± SD 1.72\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (N = 111)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (14/111)

  **12**       **García-Patterso** (1997)\                                        **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               Spain\[[@pone.0237571.ref041]\]                                    **66** women with (DM-I and DM-II)\                                                             • Intensive insulin therapy,\                                                                                                                                                                                                                                                         **Miscarriage:** (13/66)\
                                                                                  **NO-PCC**:\                                                                                    • Self-monitoring of blood glucose,\                                                                                                                                                                                                                                                  **CS deliver**y**: (**47/66)\
                                                                                  **119** women with (DM-I and DM-II)                                                             • Dietary advice.                                                                                                                                                                                                                                                                     **Congenital malformations:** (2/66)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **RDS:** (6/66)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal Hypoglycemia: (**14/66)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (15/66)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (1/66)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA**: (1/54)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (15/119)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (65/119)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (10/119)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **RDS:** (12/119)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal Hypoglycemia: (**30/119**)**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (29/119)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (2/119)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA:** (9/105)

  **13**       **Goldman (**1986) Israel\[[@pone.0237571.ref053]\]                **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **44** women with (DM-I)\                                                                       • Assessment of diabetic complications,\                                                                                                                                                                                                                                              **First trimester HbA1c:** 7.38 ± SD 0.34\
                                                                                  **NO-PCC**:\                                                                                    • Contraception advice,\                                                                                                                                                                                                                                                              (N = 44)\
                                                                                  **31** women with (DM-I)                                                                        • Glycemic control and dietary advice.                                                                                                                                                                                                                                                **CS deliver**y: (10/44)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations: (**0/44)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal Hypoglycemia: (**5/44)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **RDS:** (1/44)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 10.42 ± SD 0.47\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (N = 31)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (13/31)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (3/31)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal Hypoglycemia:** (8/31)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **RDS:** (4/31)

  **14**       **Gunton** (2000) Australia \[[@pone.0237571.ref057]\]             **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **24** pregnancies (some participants had more than one pregnancy) with (DM-I and DM-II)\       • Pregnancies planning by optimizing glycemic control before conception (i.e. intensive insulin regimen treatment and tested the blood glucose frequently).                                                                                                                           **First trimester HbA1c:** 6.6 ± SD 2.8 (N = 24)\
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          **CS deliver**y: (3/24)\
                                                                                  **69** pregnancies **(**some participants had more than one pregnancy) with (DM-I and DM-II)\                                                                                                                                                                                                                                                                                         **NO-PCC**:\
                                                                                  **Total N = of women: 61**                                                                                                                                                                                                                                                                                                                                                            **First trimester HbA1c:** 8.4 ± SD 5.4 (N = 69)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y**: (**33/69)

  **15**       **Gunton** (2002) Australia\[[@pone.0237571.ref044]\]              **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **19** pregnancies **(**some participants had more than one pregnancy) with (DM-I and DM-II)\   • Pregnancies planning by optimizing glycemic control before conception                                                                                                                                                                                                               **First trimester HbA1c:** 5.5 ± SD 1 (N = 19)\
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          **CS deliver**y: (6/19)\
                                                                                  **16** pregnancies **(**some participants had more than one pregnancy) with (DM-I and DM-II)\                                                                                                                                                                                                                                                                                         **LGA:** (5/19)\
                                                                                  **Total Number of women:**31                                                                                                                                                                                                                                                                                                                                                          **Congenital malformations:** (0/19)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC**:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 6.5 ± SD 1.5 (N = 16)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (8/11)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (1/16)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA: (**4/11)

  **16**       **Heller** (2010)\                                                 **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               United Kingdom\[[@pone.0237571.ref049]\]                           **99** women with (DM-I)\                                                                       • Insulin treatment with either Aspart or human insulin.                                                                                                                                                                                                                              **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c**: 6.24 ± SD 0.69 (N = 99)\
                                                                                  \[44 treated with Aspart Insulin\                                                                                                                                                                                                                                                                                                                                                     **NO-PCC:**\
                                                                                  55 women treated with Human Insulin\]\                                                                                                                                                                                                                                                                                                                                                **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c**: 6.24 ± SD 0.7 (N = 223)
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          
                                                                                  **223** women with (DM-I)\                                                                                                                                                                                                                                                                                                                                                            
                                                                                  \[113 treated with Aspart Insulin\                                                                                                                                                                                                                                                                                                                                                    
                                                                                  110 women treated with Human Insulin\]                                                                                                                                                                                                                                                                                                                                                

  **17**       **Hiéronimus** (2004)\                                             **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               France \[[@pone.0237571.ref046]\]                                  **24** women with (DM-I and DM-II)\                                                             Pregnancy programming: -\                                                                                                                                                                                                                                                             **First trimester HbA1c:** 6.79 ± SD 0.72 (N = 24)\
                                                                                  **NO-PCC**:\                                                                                    • Pre-conceptional specialized consultation,\                                                                                                                                                                                                                                         **Congenital malformations:** (1/24)\
                                                                                  **36** women with (DM-I and DM-II)                                                              • Intensification of glycemic self-monitoring,\                                                                                                                                                                                                                                       **NO-PCC:**\
                                                                                                                                                                                  • Optimization of insulin therapy of a preconception HbA1c close to 6%.                                                                                                                                                                                                               **First trimester HbA1c:** 8.33 ± SD 1.67 (N = 36)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (8/36)

  **18**       **Herman** (1999)\                                                 **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               USA \[[@pone.0237571.ref042]\]                                     **24** women with (DM-I)\                                                                       • Education and counselling,\                                                                                                                                                                                                                                                         **Miscarriage:** (4/24)\
                                                                                  **NO-PCC**:\                                                                                    • Glycemic control,\                                                                                                                                                                                                                                                                  **Congenital malformations:** (1/24)\
                                                                                  **74** women with (DM-I)                                                                        • Assessment of complications of diabetes such as nephropathy and retinopathy.                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (3/74)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (10/74)

  **19**       **Holmes** (2017) United Kingdom \[[@pone.0237571.ref051]\]        **PCC**:\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
                                                                                  **58** women with (DM-I and DM-II)\                                                             • Viewing DVD about preconception counselling.                                                                                                                                                                                                                                        **First trimester HbA1c:** 6.7 ± SD 0.9 (N = 58)\
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          **Miscarriage:** (1/58)\
                                                                                  **114** women with (DM-I and DM-II)                                                                                                                                                                                                                                                                                                                                                   **CS deliver**y: (37/56)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (2/57)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **GA at booking(week):** 8.3 ± SD 2.3 (N = 58)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA:** (11/57)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Maternal hypoglycemia:** (8/56)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NICU admission:** (15/56)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 7.4 ± SD 1.4 (N = 114)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (16/114)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (69/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (2/94)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **GA at booking(week):** 8.3 ± SD 3.2 (N = 109)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA:** (13/93)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Maternal hypoglycemia:** (18/101)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NICU admission:** (30/92)

  **20**       **Jaffiol** (2000)\                                                **PCC**:\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC**:\
               France \[[@pone.0237571.ref043]\]                                  **21** women with (DM-I)\                                                                       • Education,\                                                                                                                                                                                                                                                                         **Miscarriage:** (2/21)\
                                                                                  **NO-PCC**:\                                                                                    • Glycemic control,\                                                                                                                                                                                                                                                                  **CS deliver**y: (15/21)\
                                                                                  **40** women with (DM-I)                                                                        • Self-monitoring of blood glucose,\                                                                                                                                                                                                                                                  **GA at booking(week):** 6.7 ± SD 1.8 (N = 21)\
                                                                                                                                                                                  • Contraception.                                                                                                                                                                                                                                                                      **Congenital malformations:** (0/21)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **[\#](#t001fn004){ref-type="table-fn"}Perinatal mortality: (**0/21)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **RDS:** (2/21)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal Hypoglycemia: (**1/21)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery: (**7/19)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (4/40)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (21/40)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **GA at booking(week):** 11.1 ± SD 5.3 (N = 40)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations: (**3/40)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **[\#](#t001fn004){ref-type="table-fn"}Perinatal mortality:** (2/40)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **RDS:** (8/40)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal Hypoglycemia:** (7/40)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (24/34)

  **21**       **Jensen** (1986) Denmark\[[@pone.0237571.ref068]\]                **PCC**:\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC**:\
                                                                                  **9** women with (DM-I)\                                                                        • Glycemic control through continuous subcutaneous insulin infusion and conventional treatment. Initiated two months prior to conception.                                                                                                                                             **First trimester HbA1c**: 6.9 ± SD 0.2 (N = 9)\
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          **NO-PCC:**\
                                                                                  **11** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                              **First trimester HbA1c:** 7.2 ± SD 0.5 (N = 11)

  **22**       **Kallas-Koeman** (2012)\                                          **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               Canada\[[@pone.0237571.ref060]\]                                   **71** women with (DM-I and DM-II)\                                                             • Formal PCC at diabetes pregnancy clinics.                                                                                                                                                                                                                                           **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c**: 6.77 ± SD 0.97 (71)\
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          **NO-PCC:**\
                                                                                  **150** women with (DM-I and DM-II)                                                                                                                                                                                                                                                                                                                                                   **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c**: 7.63 ± SD 1.69 (N = 150)

  **23**       **Kekäläinen** (2016)\                                             **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               Finland\[[@pone.0237571.ref065]\]                                  **96** women with (DM-I)\                                                                       • Pregnancy Planning\                                                                                                                                                                                                                                                                 **First trimester HbA1c:** 6.76 ± SD 0.82 (N = 96)\
                                                                                  **NO-PCC**:\                                                                                    • Optimizing glycemic control\                                                                                                                                                                                                                                                        **Miscarriage:** (15/96)\
                                                                                  **49** of women with (DM-I)                                                                     • Medications and screening of other health problems.                                                                                                                                                                                                                                 **Preeclampsia:** (18/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (47/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (20/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (2/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA: (**35/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Shoulder dystocia: (**3/81)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal hypoglycemia:** (63/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Asphyxia: (**4/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **RDS: (**19/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 8.30 ± SD 1.14 (N = 49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (14/49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preeclampsia: (**10/49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y**: (**24/49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery: (**15/49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations: (**4/49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA: (**14 /49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Shoulder dystocia: (**3/35)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Neonatal hypoglycemia:** (30/49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Asphyxia: (**4/49)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **RDS: (**9/49)

  **24**       **Kitzmiller** (1991)\                                             **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               USA\[[@pone.0237571.ref038]\]                                      **84** women with (DM-I and DM-II)\                                                             • Glycemic and dietary control,\                                                                                                                                                                                                                                                      **Congenital malformations:** (1/84)\
                                                                                  **NO-PCC**:\                                                                                    • Education,\                                                                                                                                                                                                                                                                         **NO-PCC:**\
                                                                                  **110** women with (DM-I and DM-II)                                                             • Self-monitoring,\                                                                                                                                                                                                                                                                   **Congenital malformations:** (12/110)
                                                                                                                                                                                  • Exercise and contraception.                                                                                                                                                                                                                                                         

  **25**       **Murphy** (2010)\                                                 **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               United Kingdom\[[@pone.0237571.ref059]\]                           **181** women with (DM-I and DM-II)\                                                            • Glycemic control,\                                                                                                                                                                                                                                                                  **Miscarriage:** (28/181)\
                                                                                  **NO-PCC**:\                                                                                    • Folic acid supplementation,\                                                                                                                                                                                                                                                        **LGA:** (120/145)\
                                                                                  **495** women with (DM-I and DM-II)                                                             • Smoking cessation,\                                                                                                                                                                                                                                                                 **Congenital malformations:** (1/152)\
                                                                                                                                                                                  • Education and preconception counselling.                                                                                                                                                                                                                                            **Perinatal mortality:** (1/152)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (99/181)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (50/150)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA:** (7/145)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (71/495)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA:** (284/372)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (23/408)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (9/408)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (222/495)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (116/397)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA:** (32/372)

  **26**       **Neff** (2014)\                                                   **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               Ireland\[[@pone.0237571.ref063]\]                                  **70** women with (DM-I)\                                                                       • Insulin treatment which was continuous subcutaneous infusion and multiple daily injection.                                                                                                                                                                                          **First trimester HbA1c:** 6.9 ± SD 0.9 (N = 70)\
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          **LGA: (**17/70)\
                                                                                  **394** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                             **SGA: (**4/63)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (47/70)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage: (**7/70)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery: (**11/70)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **GA at booking(week):** 6 ± SD 2 (N = 70)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC**:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 7.8 ± SD 1.5 (N = 394)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA: (**83/394)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA:** (27/331)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (213/394)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage: (**63/394**)**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery: (**59/394)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **GA at booking(week):** 8 ± SD 6 (N = 394)

  **27**       **Gutaj** (2013)\                                                  **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               Poland\[[@pone.0237571.ref061]\]                                   **43** women with (DM-I and DM-II)\                                                             • Pregnancy planning,\                                                                                                                                                                                                                                                                **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c:** 6.15 ± SD 0.82 (N = 43)\
                                                                                  **NO-PCC**:\                                                                                    • Counseling delivered by a diabetes specialist,\                                                                                                                                                                                                                                     **NO-PCC**:\
                                                                                  **108** women with (DM-I and DM-II)                                                             • Glycemic control by making necessary changes in pharmacotherapy,\                                                                                                                                                                                                                   **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c:** 8.13 ± SD 01.85 (N = 108)
                                                                                                                                                                                  • Controlling chronic diabetic complications.                                                                                                                                                                                                                                         

  **28**       **Rosenn** (1991)\                                                 **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               USA\[[@pone.0237571.ref039]\]                                      **28** women with (DM-I)\                                                                       • Dietary advice\                                                                                                                                                                                                                                                                     **First trimester HbA1c:**8.5 ± SD 0.22 (N = 28)\
                                                                                  **NO-PCC**:\                                                                                    • Glycemic control                                                                                                                                                                                                                                                                    **Congenital malformations:** (0/28)\
                                                                                  **71** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                              **Miscarriage:** (7/28)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **GA at booking(week):** 5.5 ± SD 0.2 (N = 28)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 10 ± SD 0.32 (N = 71)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (1/71)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **GA at booking(week):** 6.8 ± SD 0.18 (N = 71)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (17/71)

  **29**       **Rowe** (1987)\                                                   **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               United Kingdom\[[@pone.0237571.ref054]\]                           **14** women with (DM-I)\                                                                       • Glycemic control,\                                                                                                                                                                                                                                                                  **First trimester HbA1c:** 9.8 ± SD 2.0 (N = 14)\
                                                                                  **NO-PCC**:\                                                                                    • Counseling,\                                                                                                                                                                                                                                                                        **Congenital malformations:** (0/14)\
                                                                                  **7** women with (DM-I)                                                                         • Blood glucose self-monitoring.                                                                                                                                                                                                                                                      **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 13.7 ± SD 3.3 (N = 7)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations: (**2/7)

  **30**       **Steel** (1982 & 1990)\                                           **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC**:\
               United Kingdom\[[@pone.0237571.ref032], [@pone.0237571.ref033]\]   **143** women with (DM-I)\                                                                      • Education,\                                                                                                                                                                                                                                                                         **First trimester HbA1c:** 8.4 ± SD 1.3 (N = 143)\
                                                                                  **NO-PCC**:\                                                                                    • Glycemic control,\                                                                                                                                                                                                                                                                  **Congenital malformations:** (2/143)\
                                                                                  **96** women with (DM-I)                                                                        • Contraception.                                                                                                                                                                                                                                                                      **Maternal hypoglycemia:** (38/143)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 10.5 ± SD 2 (N = 96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (10/96)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Maternal hypoglycemia:** (8/96)

  **31**       **Temple** (2006a &[ &]{.smallcaps} 2006b)\                        **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               United Kingdom\[[@pone.0237571.ref030], [@pone.0237571.ref031]\]   **110** women with (DM-I)\                                                                      • Glycemic control,\                                                                                                                                                                                                                                                                  **First trimester HbA1c:** 5.9 ± SD 0.9 (N = 110)\
                                                                                  **NO-PCC**:\                                                                                    • Folic acid supplementation,\                                                                                                                                                                                                                                                        **GA at booking(week):** 6.6 ± SD 1.8 (N = 110)\
                                                                                  **180** women with (DM-I)                                                                       • Smoking cessation,\                                                                                                                                                                                                                                                                 **Maternal hypoglycemia:** (47/110)\
                                                                                                                                                                                  • Education.                                                                                                                                                                                                                                                                          **Miscarriage:** (6/110)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (28/110)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preeclampsia:** (14/110)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y**: (**73/110)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA:** (48/110)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (2/110)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **[\#](#t001fn004){ref-type="table-fn"}Perinatal mortality:** (1/110)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC**:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 6.6 ± SD 1.2 (N = 180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **GA at booking(week):** 8.3 ± SD 2.6 (N = 180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Maternal hypoglycemia:** (65/180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preeclampsia:** (22/180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (118/180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Preterm delivery:** (61/180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (11/180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Miscarriage:** (22/180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA:** (78/180)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        [**[\#](#t001fn004){ref-type="table-fn"}**](#t001fn004){ref-type="table-fn"} **Perinatal mortality:** (6/180)

  **32**       **Willhoite** (1993)\                                              **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               USA\[[@pone.0237571.ref040]\]                                      **62** women with (DM-I and DM-II)\                                                             • Counseling by health professional.                                                                                                                                                                                                                                                  **Perinatal mortality:** (4/62)\
                                                                                  **NO-PCC**:\                                                                                                                                                                                                                                                                                                                                                                          **Congenital malformations:** (1/62)\
                                                                                  **123** women with (DM-I and DM-II)                                                                                                                                                                                                                                                                                                                                                   **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (26/123)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (8/123)

  **33**       **Wong (**2013)\                                                   **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               United Kingdom\[[@pone.0237571.ref062]\]                           **52** women with (DM-I and DM-II)\                                                             • HbA1c monitoring in each trimester,\                                                                                                                                                                                                                                                **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c**: 7.37 ± SD 1.95 (N = 52)\
                                                                                  **NO-PCC**:\                                                                                    • Insulin treatment,\                                                                                                                                                                                                                                                                 **Congenital malformations:** (1/52)\
                                                                                  **109** women with (DM-I and DM-II)                                                             • Pregnancies planning,\                                                                                                                                                                                                                                                              **Perinatal mortality:** (3/52)\
                                                                                                                                                                                  • Diabetes management by a diabetes (i.e. endocrinologists or general physicians with a special interest in diabetes),\                                                                                                                                                               **NO-PCC**:\
                                                                                                                                                                                  • Following up throughout pregnancy with the involvement of dietitians and diabetes educators.                                                                                                                                                                                        **[^x^](#t001fn002){ref-type="table-fn"}First trimester HbA1c:** 8.33 ± SD 2.33 (N = 109)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (10/109)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (12/109)

  **34**       **Wotherspoon** (2017)\                                            **PCC:**\                                                                                       PCC included:\                                                                                                                                                                                                                                                                        **PCC:**\
               United Kingdom \[[@pone.0237571.ref052]\]                          **455** women with (DM-I)\                                                                      • Pregnancy planning,\                                                                                                                                                                                                                                                                **First trimester HbA1c:** 7.0 ± SD 0.8 (N = 455)\
                                                                                  **NO-PCC**:\                                                                                    • Pre-pregnancy counselling (as structured advice about maintaining good blood glucose control and healthy lifestyle (with respect to diet, exercise, BMI, smoking status and alcohol consumption) before trying to become pregnant, including the need to take folate supplements.   **Pre-eclampsia:** (74/448)\
                                                                                  **292** women with (DM-I)                                                                                                                                                                                                                                                                                                                                                             **CS deliver**y: (307/454)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (12/449)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA: (**26/446)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA: (**230/446)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (15/454)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NICU admission: (**218/436)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **First trimester HbA1c:** 7.5 ± SD 1.1 (N = 292)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Pre-eclampsia:** (49/286)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **CS deliver**y: (200/286)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Perinatal mortality:** (6/284)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **SGA: (**31/284)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **LGA: (**149/284)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **Congenital malformations:** (13/291)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **NICU admission:** (178/277)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**DM-I:** Diabetes Mellitus type I**, DM-II:** Diabetes Mellitus type II, **GA:** Gestational Age**, GWG:** Gestational Weight Gain**, HbA1c:** Glycated Haemoglobin**, LGA:** Large for Gestational Age, **NICU:** Neonatal Intensive Care Unit**, NO-PCC:** No Preconception Care**, PCC:** Preconception Care**, RDS:** Respiratory Distress Syndrome, **SGA:** Small for Gestational Age

^x^ Calculated mean

^\~^ LGA and macrosomia

\# sum of stillbirth and neonatal death

10.1371/journal.pone.0237571.t002

###### Characteristics of included case control study.
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  ------------------------------------------------------------------------------------------------------------------------
  Study ID                           Participants    Intervention vs. comparison   Outcomes
  ---------------------------------- --------------- ----------------------------- ---------------------------------------
  **Garcia- Ingelmo**\               **PCC:**12\     **PCC included:**\            **PCC:**\
  1998\                              **NO-PCC:**12   • Glycaemic control           **First trimester HbA1c:** 6.7±0.58\
  Spain \[[@pone.0237571.ref067]\]                                                 **Congenital malformations:** 3/12\
                                                                                   **Macrosomia:** 6/12\
                                                                                   **NO-PCC:**\
                                                                                   **First trimester HbA1c:** 8.29±1.32\
                                                                                   **Congenital malformations:** 2/12\
                                                                                   **Macrosomia:** 4/12

  ------------------------------------------------------------------------------------------------------------------------

**NO-PCC:** No preconception care**, PCC:** pre-conception care, **HbA1c:** Glycated Haemoglobin.

10.1371/journal.pone.0237571.t003

###### Characteristics of included RCT studies.

![](pone.0237571.t003){#pone.0237571.t003g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                                      Participants                                                                                                                           Intervention vs. comparison                                                                                            Outcomes
  ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  **DCCT Research Group** 1996 USA \[[@pone.0237571.ref066]\]   94 women with 135 pregnancies in the intensive treatment group and 86 women with 135 pregnancies in the conventional treatment group   Intensive glycemic control (IGC) (multiple daily insulin injections or continuous infusion pump and self-monitoring)   **PCC:**\
                                                                                                                                                                                                                                                                                                                              **At conception HbA1c:** 7.4± SD 1.3\
                                                                                                                                                                                                                                                                                                                              (N = 132)\
                                                                                                                                                                                                                                                                                                                              **Congenital malformations:**(1/135)\
                                                                                                                                                                                                                                                                                                                              **Spontaneous abortion:**(18/135)\
                                                                                                                                                                                                                                                                                                                              **Perinatal mortality** (Intrauterine deaths)\
                                                                                                                                                                                                                                                                                                                              (5/135)\
                                                                                                                                                                                                                                                                                                                              **NO-PCC:**\
                                                                                                                                                                                                                                                                                                                              **At conception HbA1c:** 8.1 ±SD 1.7 (N = 135)\
                                                                                                                                                                                                                                                                                                                              **Congenital malformations:** (8/135)\
                                                                                                                                                                                                                                                                                                                              **Spontaneous abortion: (**14/135)\
                                                                                                                                                                                                                                                                                                                              **Perinatal mortality** (Intrauterine deaths) (9/135)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**NO-PCC:** No preconception care**, PCC:** pre-conception care, **HbA1c:** Glycated Haemoglobin.

### Interventions {#sec022}

The PPC in all the cohort studies included control and self-monitoring of blood glucose except for one study which was designed to examine the effectiveness of pre-pregnancy counseling on perinatal outcomes \[[@pone.0237571.ref040]\]. In addition to glycemic control, ten studies included screening and treatment of complications of diabetes in the PPC program \[[@pone.0237571.ref029], [@pone.0237571.ref042], [@pone.0237571.ref045], [@pone.0237571.ref050], [@pone.0237571.ref053], [@pone.0237571.ref055], [@pone.0237571.ref056], [@pone.0237571.ref058], [@pone.0237571.ref061], [@pone.0237571.ref062]\]. Eleven studies (12 reports) reported comprehensive PCC program including control and self-monitoring of blood glucose in addition to any combination of the following: folic acid supplementation, diet and exercise, smoking cessation, alcohol withdrawal advice, and discontinuation of teratogenic drugs \[[@pone.0237571.ref031], [@pone.0237571.ref038], [@pone.0237571.ref047], [@pone.0237571.ref050]--[@pone.0237571.ref052], [@pone.0237571.ref058]--[@pone.0237571.ref061], [@pone.0237571.ref063]\].

### Outcomes measure {#sec023}

In this review, a total of 14 outcomes were reported in the cohort studies, including five maternal outcomes: HbA1c in the first trimester, CS delivery, miscarriage, GA at first antenatal booking, and maternal hypoglycemia during the first trimester. There were nine neonatal outcomes (congenital malformations, perinatal mortality, preterm delivery, macrosomia/LGA, SGA, neonatal hypoglycemia, admission to NICU, RDS and shoulder dystocia). The most frequently reported outcomes were HbA1c in the first trimester (24 studies) \[[@pone.0237571.ref031], [@pone.0237571.ref032], [@pone.0237571.ref036], [@pone.0237571.ref039], [@pone.0237571.ref044], [@pone.0237571.ref046]--[@pone.0237571.ref057], [@pone.0237571.ref060]--[@pone.0237571.ref065], [@pone.0237571.ref068]\] and congenital malformations (25 studies) \[[@pone.0237571.ref029], [@pone.0237571.ref031], [@pone.0237571.ref032], [@pone.0237571.ref036]--[@pone.0237571.ref048], [@pone.0237571.ref050]--[@pone.0237571.ref054], [@pone.0237571.ref056], [@pone.0237571.ref059], [@pone.0237571.ref062], [@pone.0237571.ref065]\]. Fourteen studies examined the reduction in CS delivery in women who received PCC compared to those who did not \[[@pone.0237571.ref031], [@pone.0237571.ref041], [@pone.0237571.ref043], [@pone.0237571.ref044], [@pone.0237571.ref050]--[@pone.0237571.ref053], [@pone.0237571.ref056]--[@pone.0237571.ref059], [@pone.0237571.ref063], [@pone.0237571.ref065]\]. Eleven studies compared the miscarriage rate between the two groups \[[@pone.0237571.ref031], [@pone.0237571.ref039], [@pone.0237571.ref041]--[@pone.0237571.ref043], [@pone.0237571.ref050], [@pone.0237571.ref051], [@pone.0237571.ref055], [@pone.0237571.ref059], [@pone.0237571.ref063], [@pone.0237571.ref065]\].

Perinatal mortality \[[@pone.0237571.ref031], [@pone.0237571.ref040], [@pone.0237571.ref041], [@pone.0237571.ref043], [@pone.0237571.ref045], [@pone.0237571.ref050], [@pone.0237571.ref052], [@pone.0237571.ref056], [@pone.0237571.ref059], [@pone.0237571.ref062]\] and preterm delivery \[[@pone.0237571.ref031], [@pone.0237571.ref041], [@pone.0237571.ref043], [@pone.0237571.ref050], [@pone.0237571.ref056], [@pone.0237571.ref058], [@pone.0237571.ref059], [@pone.0237571.ref063], [@pone.0237571.ref065]\] were reported in ten and nine studies respectively, while LGA, macrosomia \[[@pone.0237571.ref031], [@pone.0237571.ref044], [@pone.0237571.ref050]--[@pone.0237571.ref052], [@pone.0237571.ref056], [@pone.0237571.ref059], [@pone.0237571.ref063], [@pone.0237571.ref065]\] SGA \[[@pone.0237571.ref041], [@pone.0237571.ref050], [@pone.0237571.ref052], [@pone.0237571.ref056], [@pone.0237571.ref059], [@pone.0237571.ref063]\], and neonatal hypoglycemia \[[@pone.0237571.ref041], [@pone.0237571.ref043], [@pone.0237571.ref050], [@pone.0237571.ref053], [@pone.0237571.ref065]\] were reported in nine, six and five studies respectively. Admission to NICU \[[@pone.0237571.ref050]--[@pone.0237571.ref052], [@pone.0237571.ref056]\], and neonatal RDS \[[@pone.0237571.ref041], [@pone.0237571.ref043], [@pone.0237571.ref053], [@pone.0237571.ref065]\] were reported in four studies. The least reported outcomes were maternal hypoglycemia in three studies (all reported results among type 1 diabetes) \[[@pone.0237571.ref031], [@pone.0237571.ref033], [@pone.0237571.ref051]\] and shoulder dystocia in two studies \[[@pone.0237571.ref050], [@pone.0237571.ref065]\].

### Assessment of the methodological quality of the included studies {#sec024}

We used the NOS Form for Cohort Studies to determine the level of bias of cohort studies included in this review ([Table 4](#pone.0237571.t004){ref-type="table"}). 21 studies were determined to be at a low risk of bias \[[@pone.0237571.ref030]--[@pone.0237571.ref033], [@pone.0237571.ref041], [@pone.0237571.ref043], [@pone.0237571.ref045], [@pone.0237571.ref049]--[@pone.0237571.ref052], [@pone.0237571.ref055], [@pone.0237571.ref057]--[@pone.0237571.ref065]\], while 15 studies were judged to be at a high risk of bias \[[@pone.0237571.ref027]--[@pone.0237571.ref029], [@pone.0237571.ref036]--[@pone.0237571.ref040], [@pone.0237571.ref042], [@pone.0237571.ref044], [@pone.0237571.ref046]--[@pone.0237571.ref048], [@pone.0237571.ref053], [@pone.0237571.ref054], [@pone.0237571.ref056], [@pone.0237571.ref068]\]. Some of the studies at a high risk of bias were initially designed to assess aspects of PPC other than its effectiveness in improving maternal and perinatal outcomes, hence the poor methodological design when assessed with the NOS \[[@pone.0237571.ref040], [@pone.0237571.ref042], [@pone.0237571.ref056]\].

10.1371/journal.pone.0237571.t004

###### Risk of bias assessment of the included studies.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                             Selection   Comparability   Outcome   Total   Risk of Bias assessment/Notes                                          
  --------------------------------------------------------------------------------- ----------- --------------- --------- ------- ------------------------------- --------- --------- ---- --------- --- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Boulot 2003\[[@pone.0237571.ref045]\]**                                         \*          \*              \*        \*      \*                              \*        \*        \*   \*        9   **Low risk**

  **Cousins 1991\[[@pone.0237571.ref037]\]**                                        \*          \*              \*        \*      unclear                         unclear   \*        \*   unclear   6   **High risk**\
                                                                                                                                                                                                         No comparability

  **Damm 1989\[[@pone.0237571.ref036]\]**                                           \*          \*              \*        \*      unclear                         unclear   unclear   \*             5   **High risk**\
                                                                                                                                                                                                         Unclear group comparability

  **Dicker 1988\[[@pone.0237571.ref055]\]**                                                     \*              \*        \*      \*                              \*        \*        \*   \*        8   **Low risk**

  **Egan 2016\[[@pone.0237571.ref050]\]**                                                       \*              \*        \*      \*                              \*        \*        \*   \*        8   **Low risk**

  **Cyganek 2010\[[@pone.0237571.ref058]\]**                                        \*          \*              \*        \*      \*                              \*        \*        \*   \*        9   **Low risk**

  **Cyganek 2016 \[[@pone.0237571.ref064]\]**                                       \*          \*              \*        \*      \*                                        \*        \*   \*        8   **Low risk**

  **Dunne 1999 \[[@pone.0237571.ref056]\]**                                         \*          \*              \*        \*                                                \*        \*   \*        7   **High risk**\
                                                                                                                                                                                                         The study was an audit, groups were different in smoking, no statistical adjustment done.

  **Evers 2004\[[@pone.0237571.ref047]\]**                                          \*          \*              \*        \*      Unclear                         Unclear   \*        \*   \*        7   **High risk**\
                                                                                                                                                                                                         Confounding factors such as smoking, education level and social class were not examined. The results of HbA1c during the first trimester were not available for 29% of the whole study group

  **Fuhrmann 1983, 1984, 1986\[[@pone.0237571.ref027]--[@pone.0237571.ref029]\]**               \*              \*        \*      Unclear                         Unclear   \*        \*             5   **High risk**\
                                                                                                                                                                                                         no description of the possible confounding factors or adjustment

  **Galindo 2006 \[[@pone.0237571.ref048]\]**                                       \*          \*              \*        \*      unclear                         unclear   \*        \*   \*        7   **High risk**\
                                                                                                                                                                                                         It is unclear if factors influencing the outcome were similar in both groups, no statistical adjustment was done

  **García-Patterson 1997\[[@pone.0237571.ref041]\]**                                           \*              \*        \*      \*                              unclear   \*        \*   \*        7   **Low risk**

  **Goldman 1986\[[@pone.0237571.ref053]\]**                                                    \*              \*        \*      \*                              Unclear   \*        \*   \*        7   **High risk**\
                                                                                                                                                                                                         Difference in smoking and BMI between the groups not assessed

  **Gunton 2000\[[@pone.0237571.ref057]\]**                                                     \*              \*        \*      \*                              \*        \*        \*             7   **Low risk**

  **Gunton 2002 \[[@pone.0237571.ref044]\]**                                        \*          \*                        \*      Unclear                         Unclear   \*        \*   \*        6   **High risk**\
                                                                                                                                                                                                         Difference in the duration of diabetes between the groups not controlled for

  **Gutaj 2013\[[@pone.0237571.ref061]\]**                                                      \*              \*                \*                              \*        \*        \*   \*        7   **Low risk**

  **Heller 2010 \[[@pone.0237571.ref049]\]**                                        \*          \*              \*        \*      \*                              \*        \*        \*   \*        9   **Low risk**

  **Hiéronimus 2004\[[@pone.0237571.ref046]\]**                                                 \*              \*        \*      Unclear                         Unclear   \*        \*   \*        6   **High risk**\
                                                                                                                                                                                                         no description of the possible confounding factors or adjustment

  **Herman 1999 \[[@pone.0237571.ref042]\]**                                                    \*              \*        \*      \*                              Unclear   \*        \*             6   **High risk**\
                                                                                                                                                                                                         The groups are different in duration of diabetes other confounders not addressed, no adjustment

  **Holmes 2017\[[@pone.0237571.ref051]\]**                                                                     \*        \*      \*                              \*        \*        \*   \*        7   **Low risk**

  **Jaffiol 2000\[[@pone.0237571.ref043]\]**                                                    \*              \*        \*      \*                              \*        \*        \*   \*        8   **Low risk**

  **Jensen 1986\[[@pone.0237571.ref068]\]**                                                     \*                        \*      Unclear                         Unclear   \*        \*             4   **High risk**\
                                                                                                                                                                                                         Differences in the severity of diabetes, five of the 11 control women were treated in the diabetic clinic in the hospital before pregnancy so they knew about the importance of glycemic control

  **Kallas-Koeman 2012\[[@pone.0237571.ref060]\]**                                  \*          \*              \*        \*      \*                              \*        \*        \*   \*        9   **Low risk**

  **Kekäläinen 2016 \[[@pone.0237571.ref065]\]**                                                \*              \*        \*      \*                              \*        \*        \*   \*        8   **Low risk**

  **Kitzmiller 1991\[[@pone.0237571.ref038]\]**                                                 \*              \*        \*      Unclear                         Unclear   \*        \*   \*        6   **High risk** Unclear if there is difference between the groups.

  **Murphy 2010\[[@pone.0237571.ref059]\]**                                         \*          \*              \*        \*      \*                              \*        \*        \*   \*        9   **Low risk**

  **Neff 2014\[[@pone.0237571.ref063]\]**                                           \*          \*              \*        \*      \*                              \*        \*        \*             8   **Low risk**

  **Rosenn 1991\[[@pone.0237571.ref039]\]**                                                     \*              \*        \*      Unclear                         Unclear   \*        \*             5   **High risk**\
                                                                                                                                                                                                         52% lost to follow up, different baseline characteristics including duration of diabetes, age, complications of diabetes

  **Rowe 1987 \[[@pone.0237571.ref054]\]**                                                      \*                        \*      Unclear                         Unclear             \*   \*        4   **High risk**\
                                                                                                                                                                                                         no description of the possible confounding factors or adjustment

  **Steel 1982, 1990 \[[@pone.0237571.ref032], [@pone.0237571.ref033]\]**           \*          \*              \*        \*      \*                                        \*        \*   \*        7   **Low risk**\
                                                                                                                                                                                                         There is no significant clinical age difference between the groups. However, there is different number of smokers. No regression analysis was done to address this difference

  **Temple a & b 2006 \[[@pone.0237571.ref030], [@pone.0237571.ref031]\]**          \*          \*              \*        \*      \*                              \*        \*        \*   \*        9   **Low risk**

  **Willhoite 1993\[[@pone.0237571.ref040]\]**                                      \*          \*              unclear   \*                                                          \*   \*        5   **High risk**\
                                                                                                                                                                                                         Base line characteristics of the two groups were significantly different in age, duration of diabetes and smoking. The two groups did not receive the same antenatal intra-partum and postnatal care.

  **Wong 2013 \[[@pone.0237571.ref062]\]**                                                      \*              \*        \*      \*                              \*        \*        \*   \*        8   **Low risk**

  **Wotherspoon 2017\[[@pone.0237571.ref052]\]**                                    \*          \*                        \*      \*                              \*        \*        \*   \*        8   **Low risk**
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). The number of stars represents the risk of bias; the maximum number of stars is nine, studies were classified as "low risk of bias" if they received a score of six stars or more, along with at least one star in the comparability domain. Studies at "high risk of bias" scored less than six stars or scored no stars in comparability domain, irrespective of the number of stars scored.

The cohort studies included in this review ([Table 1](#pone.0237571.t001){ref-type="table"}) had adequate description of participants including comparison between the PPC group and the control group regarding some confounding factors such as the duration of diabetes and frequency of renal and vascular complications. However, most studies did not address the effect of the confounding factors on the outcomes except for ten studies (11 reports) which used regression analysis to evaluate the independent effect of the PPC \[[@pone.0237571.ref031], [@pone.0237571.ref045], [@pone.0237571.ref051], [@pone.0237571.ref052], [@pone.0237571.ref057]--[@pone.0237571.ref060], [@pone.0237571.ref063], [@pone.0237571.ref065]\]. In most cohort studies, blinding of the control group was adequate because they were recruited after the inception of pregnancy while attending the antenatal care. In four studies, \[[@pone.0237571.ref033], [@pone.0237571.ref038], [@pone.0237571.ref049], [@pone.0237571.ref050]\] blinding was inadequate as the control groups were invited to participate in the PCC program and hence were informed about it. All participants received the same antenatal and postnatal care except for six studies \[[@pone.0237571.ref042], [@pone.0237571.ref047], [@pone.0237571.ref049]--[@pone.0237571.ref052]\] where participants were followed up in different health settings. In all cohort studies, the compliance of participants to follow up was adequate except for Rosenn et al \[[@pone.0237571.ref039]\] where 52% of the PCC group were lost to follow-up, and Jensen et al \[[@pone.0237571.ref068]\] where 3 out of 11 participants in control group did not comply with study protocol as they rejected the self-glucose monitoring. The assessors of the outcomes were not blinded to the participants\' allocation; however, we do not believe this would have introduced bias due to the objective nature of the outcomes in this review.

One case control study was included in this review \[[@pone.0237571.ref067]\]. The study encompassed a small sample size which included 12 cases each for cases and control. Both recall bias and detection bias cannot be excluded.

One trial was included in this review \[[@pone.0237571.ref066]\] ([Table 3](#pone.0237571.t003){ref-type="table"}). The design of the trial was not clear; neither the method of randomization nor the allocation concealment was described. In addition to that, lack of blinding introduced bias because both groups were aware of the importance of the glycemic control and the complications of diabetes during pregnancy.

### Effects of intervention {#sec025}

Fourteen outcomes were identified after examining all the studies; meta-analysis was possible for 34 cohort studies with 8199 participants.

*Gestational age at booking for antenatal care*. The results of the meta-analysis on the effect of PCC on the early booking for antenatal care showed that women who attended PCC booked approximately ten days earlier for antenatal care (MD 1.31; 95% CI: 1.40--1.23); five studies, 1081 women very low-certainty evidence)) ([Fig 2](#pone.0237571.g002){ref-type="fig"}) ([Table 5](#pone.0237571.t005){ref-type="table"}). The quality of evidence was downgraded from low-grade (observational study) to very low-grade due to the high risk of bias in the study with the largest weight \[[@pone.0237571.ref039]\] and high unexplained heterogeneity ([Table 6](#pone.0237571.t006){ref-type="table"}).

![The mean gestational age at the time of the first antenatal visit from five studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.](pone.0237571.g002){#pone.0237571.g002}

10.1371/journal.pone.0237571.t005

###### Pooled estimates effect of preconception care.

![](pone.0237571.t005){#pone.0237571.t005g}

  Outcome                                         No of Studies   No of Participants   Effect estimate Risk Ratio \[95% CI\]
  ----------------------------------------------- --------------- -------------------- ---------------------------------------
  Congenital malformations                        25              5903                 0.29 \[0.21, 0.40\]
  Maternal hypoglycemia                           3               686                  1.38 \[1.07, 1.79\]
  Preterm delivery                                9               2414                 0.85 \[0.73, 0.99\]
  Perinatal mortality                             10              3071                 0.46 \[0.30, 0.73\]
  Small for gestational age                       6               2261                 0.52 \[0.37, 0.75\]
  Admission to neonatal intensive care unit       4               1322                 0.75 \[0.67, 0.84\]
  Cesarean section delivery                       14              3641                 1.02 \[0.96, 1.07\]
  Miscarriage                                     11              2698                 0.86 \[0.70, 1.06\]
  Large for gestational age / macrosomia          9               2787                 1.06 \[0.97, 1.15\]
  Neonatal hypoglycemia                           5               880                  0.93 \[0.74, 1.18\]
  Respiratory distress syndrome                   4               466                  0.78 \[0.47, 1.29\]
  Shoulder dystocia                               2               530                  0.28 \[0.07, 1.12\]
                                                                                       **Mean Difference \[95% CI\]**
  Gestational age at booking for antenatal care   5               1081                 -1.31 \[-1.40, -1.23\]
  HbA1c in the first trimester                    24              4927                 -1.27 \[-1.33, -1.22\]

**CI**: Confidence Interval.

10.1371/journal.pone.0237571.t006

###### Summary of findings table.

![](pone.0237571.t006){#pone.0237571.t006g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \[Preconception care\] compared to \[no preconception care\] or \[routine care\] for \[improving maternal and perinatal outcomes\]                                                                                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------- ----------------------------------- --------------- ----------------------------------------------------------------------------------------
  **Patient or population**: \[improving maternal and perinatal outcomes\]\                                                                                                                                                                                                                                                                                           
  **Setting**: Hospital setting\                                                                                                                                                                                                                                                                                                                                      
  **Intervention**: \[Preconception care\]\                                                                                                                                                                                                                                                                                                                           
  **Comparison**: \[no preconception care\] or \[routine care\]                                                                                                                                                                                                                                                                                                       

  Outcomes                                                                                                                             **Anticipated absolute effects**[^**\***^](#t006fn001){ref-type="table-fn"} (95% CI)   Relative effect (95% CI)                              № of participants (studies)   Certainty of the evidence (GRADE)   Comments        

  **Risk with \[no preconception care\] or \[routine care\]**                                                                          **Risk with \[Preconception care\]**                                                                                                                                                                                           

  Congenital malformations follow up: mean 9 months [^a^](#t006fn008){ref-type="table-fn"}                                             70 per 1,000                                                                           **20 per 1,000** (15 to 28)                           **RR 0.29** (0.21 to 0.40)    5903 (25 observational studies)     ⨁⨁⨁⨁ HIGH       \[Preconception care\] results in large reduction in congenital malformations.

  Perinatal mortality follow up: mean 9 months [^b^](#t006fn009){ref-type="table-fn"}                                                  46 per 1,000                                                                           **21 per 1,000** (13 to 33)                           **RR 0.46** (0.30 to 0.73)    3071 (10 observational studies)     ⨁⨁⨁◯ MODERATE   \[Preconception care\] results in large reduction in perinatal mortality.

  Gestational age at booking follow up: mean 9 months [^c^](#t006fn010){ref-type="table-fn"}                                           The mean gestational age at booking was **8.5** Weeks                                  mean **1.31 Weeks fewer** (1.4 fewer to 1.23 fewer)   \-                            1081 (5 observational studies)      ⨁◯◯◯ VERY LOW   \[Preconception care\] may result in a slight reduction in gestational age at booking.

  Hemoglobin A1c (HbA1c) follow up: mean 9 months [^d^](#t006fn011){ref-type="table-fn"}                                               The mean hemoglobin A1c was **8.3**%                                                   mean **1.32% lower** (1.34 lower to 1.23 lower)       \-                            4927 (24 observational studies)     ⨁⨁⨁◯ MODERATE   \[Preconception care\] likely results in a reduction in HbA1c.

  Maternal hypoglycemia follow up: mean 9 months [^e^](#t006fn012){ref-type="table-fn"}                                                241 per 1,000                                                                          **333 per 1,000** (258 to 432)                        **RR 1.38** (1.07 to 1.79)    686 (3 observational studies)       ⨁◯◯◯ VERY LOW   \[Preconception care\] has no effect on Maternal hypoglycemia

  Preterm delivery follow up: mean 9 months [^**f**^](#t006fn013){ref-type="table-fn"}                                                 250 per 1,000                                                                          **213 per 1,000** (183 to 248)                        **RR 0.85** (0.73 to 0.99)    2414 (9 observational studies)      ⨁⨁⨁◯ MODERATE   \[Preconception care\] likely results in a slight reduction in preterm delivery.

  Small for gestational age follow up: mean 9 months [^**g**^](#t006fn014){ref-type="table-fn"}                                        88 per 1,000                                                                           **46 per 1,000** (32 to 66)                           **RR 0.52** (0.37 to 0.75)    2261 (6 observational studies)      ⨁⨁⨁◯ MODERATE   \[Preconception care\] reduces small for gestational age.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI = Confidence interval; RR = Risk ratio

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

^**a**^ Upgraded to high because of large effect size, consistency of direction of effect, no indirectness of evidence, and no heterogeneity or publication bias.

^**b**^ Upgraded to moderate due to the narrow confidence intervals, consistency of direction of effect, no indirectness of evidence, and low risk of bias, no heterogeneity or publication bias.

^**c**^ Downgraded to very low-grade due to the high risk of bias in the study with the largest weight \[[@pone.0237571.ref039]\] and high unexplained heterogeneity

^**d**^ Upgraded to moderate-certainty level because of low bias (77% of the participants were from studies at low risk of bias), while heterogeneity can be explained by long span of time between the first and the last study (1982 and 2017), The publication bias can be explained with the heterogeneity.

^**e**^ Downgraded to very low-level certainty because, inconsistency, low bias and high heterogeneity

^**f**^ Upgraded to moderate-certainty level because of narrow confidence intervals, consistency of direction of effect, no indirectness of evidence, low risk of bias, low heterogeneity, no evidence of selective reporting.

^**g**^ Upgraded to moderate-certainty level because the large effect size with precise narrow confidence interval, consistency of direction of effect, no indirectness of evidence, and no heterogeneity and no evidence of selective reporting.

*Congenital malformations*. The result of the meta-analysis on the effect of PCC on congenital malformations suggested that PCC resulted in a large reduction in congenital malformations (RR 0.29; 95% CI: 0.21--0.40, 25 studies; 5903 women; high-certainty evidence) ([Fig 3](#pone.0237571.g003){ref-type="fig"}) ([Table 5](#pone.0237571.t005){ref-type="table"}). We considered the body of evidence for the effect of PCC on the reduction of congenital malformations to be high quality mainly due to the large effect size with precise and narrow confidence intervals, consistency of direction of effect throughout most of the included studies, no indirectness of evidence, and no heterogeneity or publication bias. Bias in the included studies was considered moderate (59% of the participants were from studies at low-risk of bias) ([Fig 3](#pone.0237571.g003){ref-type="fig"}, [Table 6](#pone.0237571.t006){ref-type="table"}).

![Risk ratio for congenital malformations from 25 studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.](pone.0237571.g003){#pone.0237571.g003}

*HbA1c*. Meta-analysis of 24 studies which reported HbA1c showed that PCC likely results in a reduction in HbA1c in the first trimester of pregnancy by an average of 1.27%; (MD 1.27; 95% CI: 1.33--1.22; 4927 women; moderate-certainty evidence) ([Fig 4](#pone.0237571.g004){ref-type="fig"}) (Tables [5](#pone.0237571.t005){ref-type="table"} & [6](#pone.0237571.t006){ref-type="table"}). We considered bias in the included studies low (77% of the participants were from studies at low risk of bias) ([Fig 4](#pone.0237571.g004){ref-type="fig"}, [Table 6](#pone.0237571.t006){ref-type="table"}), while heterogeneity can be explained by long span of time between the first and the last study (1982 and 2017), during which time many innovations in the management of diabetes has occurred with substantial reduction in the target level of HbA1c. The apparent publication bias in this outcome can be explained with the heterogeneity associated with this analysis.

![First trimester means values of glycosylated hemoglobin (HbA1c) from 24 studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.](pone.0237571.g004){#pone.0237571.g004}

*Maternal hypoglycemia*. We are uncertain about the effect of PCC on maternal hypoglycemia during the first trimester of pregnancy; (RR 1.38; 95% CI: 1.07--1.79); three studies; 686 women; very low-certainty evidence) ([Fig 5](#pone.0237571.g005){ref-type="fig"}) ([Table 5](#pone.0237571.t005){ref-type="table"}). The grade of evidence was downgraded from low to very low due to inconsistency of the direction of effect and high heterogeneity (I^2^ = 76%) in the included studies ([Table 6](#pone.0237571.t006){ref-type="table"}). The true effect is likely to be substantially different from the effect estimated in this review.

![Risk ratio for maternal hypoglycaemia from three studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.](pone.0237571.g005){#pone.0237571.g005}

*Preterm delivery*. The results of the meta-analysis on the effect of PCC on preterm delivery indicate that PCC lead to a slight reduction in preterm delivery rate among women with diabetes (RR 0.85; 95% CI: 0.73--0.99; nine studies, 2414 women; moderate-certainty evidence) ([Fig 6](#pone.0237571.g006){ref-type="fig"}) ([Table 5](#pone.0237571.t005){ref-type="table"}). We upgraded the body of evidence for the effect of PCC on the reduction of preterm delivery to moderate quality. This upgrade was based on the narrow confidence intervals around the point estimate, consistency of direction of effect in most of the included studies, no indirectness of evidence, low risk of bias of the body of evidence as only 1.9% of the participants were from one study with high risk of bias. The low heterogeneity with no evidence of selective reporting increase our confidence in the outcome of a small reduction in preterm delivery ([Fig 6](#pone.0237571.g006){ref-type="fig"}, [Table 6](#pone.0237571.t006){ref-type="table"})

![Risk ratio for preterm delivery from nine studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.](pone.0237571.g006){#pone.0237571.g006}

*Perinatal mortality*. The meta-analysis results on the effect of PCC on perinatal mortality indicates that PCC results in a large reduction in perinatal mortality (RR 0.46; 95% CI: 0.30--0.73; ten studies; 3071 women; moderate-certainty evidence) ([Fig 7](#pone.0237571.g007){ref-type="fig"}) ([Table 5](#pone.0237571.t005){ref-type="table"}). The quality of evidence has been upgraded to moderate due to the narrow confidence intervals, consistency of direction of effect in most of the included studies, no indirectness of evidence, and low risk of bias of the body of evidence as only 7.6% of the participants were from two studies at high risk of bias and no heterogeneity or publication bias.

![Risk ratio for perinatal mortality from ten studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.](pone.0237571.g007){#pone.0237571.g007}

*Small for gestational age*. The result of the meta-analysis indicates that PCC may result in large reduction in SGA (RR 0.52; 95% CI: 0.37--0.75; six studies, 2261 women; moderate-certainty evidence) ([Fig 8](#pone.0237571.g008){ref-type="fig"}) ([Table 5](#pone.0237571.t005){ref-type="table"}). We upgraded the body of evidence for the effect of PCC on the reduction of SGA to moderate-quality on account of the large effect size (48% reduction in SGA) with precise narrow confidence interval, consistency of direction of effect throughout the included studies, no indirectness of evidence, and no heterogeneity and no evidence of selective reporting. We considered bias in the included studies as low (2% of the participants were from one study at high risk of bias) ([Fig 8](#pone.0237571.g008){ref-type="fig"}, [Table 6](#pone.0237571.t006){ref-type="table"}).

![Risk ratio for small for gestational age from six studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.](pone.0237571.g008){#pone.0237571.g008}

*NICU admission*. The result of the meta-analysis on the effect of PCC on admission to NICU indicates that PCC may reduce the rate of NICU admissions (RR 0.75; 95% CI: 0.67--0.84; four studies; 1322 women; moderate-certainty evidence) ([Fig 9](#pone.0237571.g009){ref-type="fig"}) ([Table 5](#pone.0237571.t005){ref-type="table"}). The body of evidence was upgraded owing to precise narrow confidence intervals, consistency of direction of effect, no indirectness of evidence, and no heterogeneity and no evidence of selective reporting. We considered bias in the included studies as low.

![Risk ratio for neonatal intensive care unit admission from four studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.](pone.0237571.g009){#pone.0237571.g009}

### Other outcomes {#sec026}

Meta-analysis showed that the PCC may have little or no effect in reducing the CS rate (RR 1.02; 95% CI: 0.96--1.07; 14 studies; 3641 women; low-certainty evidence), miscarriage rate (RR 0.86; 95% CI: 0.70--1.06; 11 studies; 2698 women; low- certainty evidence), macrosomia rate, (RR 1.06; 95% CI: 0.97--1.15; nine studies; 2787 women, low- certainty evidence), neonatal hypoglycemia (RR 0.93; 95% CI: 0.74--1.18; five studies; 880 women; low- certainty evidence), RDS (RR 0.78; 95% CI: 0.47--1.29; four studies; 466 women; very low- certainty evidence) and shoulder dystocia (RR 0.28; 95% CI: 0.07--1.12; 2 studies; 530 women; very low- certainty evidence).

### Results of sensitivity analysis {#sec027}

We performed sensitivity analysis by excluding studies with high risk of bias from the meta-analysis. Overall, results and conclusions were not changed (Figs [1](#pone.0237571.g001){ref-type="fig"}--[7](#pone.0237571.g007){ref-type="fig"}, [S3 File](#pone.0237571.s004){ref-type="supplementary-material"}).

*Publication bias*. We examined the possibility of publication bias by evaluating the asymmetry of the Funnel Plots ([Fig 10](#pone.0237571.g010){ref-type="fig"}). Analysis of the effect of PCC on congenital malformations and perinatal mortality ([Fig 10A & 10B](#pone.0237571.g010){ref-type="fig"}) demonstrated symmetrical distribution of the studies which can reasonably exclude publication bias. Analysis of the effect on HbA1C, showed asymmetrical distribution of the studies ([Fig 10C](#pone.0237571.g010){ref-type="fig"}), however this can be explained by the marked heterogeneity associated with this outcome \[[@pone.0237571.ref069]\]. We found no evidence of selective reporting of outcomes in all included studies.

![Funnel plots for studies included in the meta-analysis for the effect of PCC on congenital anomalies (a), perinatal mortality (b) and HbA1c (c).](pone.0237571.g010){#pone.0237571.g010}

Discussion {#sec028}
==========

The results of this review showed that PCC for mothers with pregestational diabetes is effective in improving the outcomes for several maternal and neonatal complications associated with pregestational diabetes. PCC results in a large reduction in congenital malformations. It probably results in a reduction of HbA1c in the first trimester of pregnancy, perinatal mortality and in slightly earlier booking of mothers for antenatal care. PCC is likely to result in a slight reduction of preterm birth rate. We are uncertain about the effect of PCC on maternal hypoglycemia during the first trimester of pregnancy.

Congenital malformations are one of the principal contributors to the high perinatal mortality observed in pregnancies complicated with pregestational diabetes \[[@pone.0237571.ref007], [@pone.0237571.ref008], [@pone.0237571.ref070], [@pone.0237571.ref071]\]. Maternal hyperglycemia at the time of organogenesis is the main teratogen \[[@pone.0237571.ref072], [@pone.0237571.ref073]\]. Evidence from clinical and experimental studies showed that hyperglycemia leads to the production of reactive oxygen species and depletion of antioxidants, which in turn causes intracellular oxidative stress, cell injury and cell death at the time of organogenesis \[[@pone.0237571.ref074], [@pone.0237571.ref075]\]. It is not surprising that PCC has a large effect on reducing the rate of congenital malformations as it provides the right window of opportunity for optimum control of hyperglycemia before the early critical weeks of conception and organogenesis. Another intervention with proven effectiveness in the prevention of congenital malformations in this high-risk group is preconception folic acid supplementation \[[@pone.0237571.ref076], [@pone.0237571.ref077]\]. Folic acid supplementation was part of almost all PCC interventions of the studies included in this review and may have contributed to the large effect of PCC in reducing congenital malformations rate.

The results of this review showed that women who received PCC achieved better control of hyperglycemia compared to those who didn't attend PCC as evident by the significantly lower mean HbA1c level of the intervention group compared to the control group. Many studies confirmed the incremental increase in the rate of adverse pregnancy outcomes, among women with diabetes~~,~~ with the increase in the level of HbA1c \[[@pone.0237571.ref078]--[@pone.0237571.ref081]\] and the significant risk reduction in congenital malformations with one percent reduction in HbA1c level \[[@pone.0237571.ref082]\].

The etiology of preterm birth is complex and many medical, socioeconomic, and psychological factors interplay in the causation of preterm delivery \[[@pone.0237571.ref083]\]. Nevertheless, mothers with diabetes are at greater risk of preterm birth compared to the background population \[[@pone.0237571.ref006]\].

A recently published systematic review and modelling analysis of the global estimate of the rate of preterm birth estimated that 14.84 million preterm live births were born in the year 2014, with the majority born in low- and middle-income countries \[[@pone.0237571.ref084]\]. Preterm birth is the leading cause of under-five mortality and one of the main causes of both short and long-term morbidity \[[@pone.0237571.ref085], [@pone.0237571.ref086]\]. In addition, preterm birth is associated with high cost to the health system and the families of the preterm born infant \[[@pone.0237571.ref087]\]. Based on the above account, the reduction in the prevalence of preterm birth achieved by the attendance of PCC will have a considerable impact on the perinatal mortality and neonatal and infant morbidity for children born to mothers with pregestational diabetes. This assertion has been confirmed by the marked reduction in perinatal mortality and in the admission to NICU for infants of mothers who received PCC compared to those who did not in this review.

The results of this review showed a significant reduction in the rate of SGA in women who attended PCC. This effect maybe secondary to the significant reduction in congenital malformations rate. The association between SGA and congenital malformations, especially those for the heart and the urinary tract, has been documented in published reports \[[@pone.0237571.ref088], [@pone.0237571.ref089]\]. Nevertheless, we cannot exclude the effect of healthy lifestyle promotion including smoking cessation, weight control, and teratogenic drugs avoidance as part of many PCC programs, which are factors contributing to the reduction in the rate of SGA \[[@pone.0237571.ref090]\].

The effects of PCC on the reduction of congenital malformations, improved glycemic control in the first trimester of pregnancy, reduced preterm delivery, and SGA rate reflected positively on the substantial reduction of 54% in perinatal mortality rate in women who attended PCC compared to those who did not ([Fig 7](#pone.0237571.g007){ref-type="fig"}, [Table 6](#pone.0237571.t006){ref-type="table"}).

Meta-analysis results showed that the effect of PCC on maternal hypoglycemia was of very low-certainty level. The three included studies had a low risk of bias but a high level of heterogeneity and inconsistency of direction of effect. Studies included were conducted in different time periods, during which time many innovations were made in the management of diabetes, which explains the heterogeneity level ([S3 File](#pone.0237571.s004){ref-type="supplementary-material"}, [Fig 8](#pone.0237571.g008){ref-type="fig"}). Direction, magnitude and certainty about the effect of PCC on maternal hypoglycemia may change with conduction of additional studies addressing this outcome"

We are not surprised that PCC had little or no effects on some outcomes such as macrosomia, shoulder dystocia and CS delivery rate, which may be influenced by perinatal care rather than PCC. Similarly, PCC had no effect on miscarriage rate, this can be explained by the late attendance of the control group for antenatal care by which time many events of miscarriage had already occurred. This assumption is further supported by the significance of early booking for antenatal care of the intervention group shown in this review.

Based on our previous systematic review results, an economic evaluation study found that pregestational diabetes lifetime societal cost is \$5.5 billion. However, the study did not evaluate the cost of the recommended universal PCC and the amount of saving with such implementation \[[@pone.0237571.ref013]\]. Another recently published study \[[@pone.0237571.ref050]\] showed relatively low saving by provision of PCC to diabetic women compared to routine care. This was explained by the improvement in obstetrics care which may have attenuated potential savings in addition to the poor utilization of PCC as only 40--60% of the target population attend the service \[[@pone.0237571.ref050]\]. It is worth noting that these studies were conducted in high income countries which makes it difficult to generalize the results to Low and Middle-Income Countries (LMICs) with different economic constrains and health services provision.

In most settings, nearly 50% of pregnancies complicated with diabetes are unplanned, hence this group of women are unlikely to attend PCC service \[[@pone.0237571.ref091]--[@pone.0237571.ref093]\]. Qualitative studies which investigated the reasons behind poor utilization of PCC showed that women with diabetes who did not attend PCC are more frequently unmarried, have modest education attainment and are unemployed \[[@pone.0237571.ref094]\]. Other factors include lack of knowledge and attitude of women with diabetes towards fertility, contraception, and the negative message about complications of diabetes in pregnancy rather than the benefits of PCC they tend to receive from healthcare providers \[[@pone.0237571.ref095]\]. However, nation-wide programs, which addressed many barriers to the utilization of PCC, had moderate success in increasing attendance for PCC for women with diabetes \[[@pone.0237571.ref050]\].

It is worth mentioning that all studies included in this review were conducted in high income countries, which may have underestimated the effect of PCC on many outcomes considering the projected increased prevalence of pregestational diabetes in LMICs and the limited resources for antenatal and neonatal care.

Strengths and limitations {#sec029}
-------------------------

This review is a comprehensive assessment of all important maternal, perinatal outcomes which could be improved by a variety of interventions in the preconception period. The review included a large number of studies and participants. The use of the GRADE tool to evaluate the body of evidence has improved our certainty about the effectiveness of PCC for the main outcomes. The results of this review concur with previously published reviews on the effectiveness of PCC \[[@pone.0237571.ref009], [@pone.0237571.ref016]\]. However, it provides higher quality of evidence with high certainty for the main important outcomes indicating that further research is unlikely to change the conclusion about the effectiveness of PCC in these outcomes.

We are aware of the limitations of this review including the uncertainty about the feasibility and the applicability of PCC in LMICs, as all the included studies were conducted in high income countries, especially if we consider the high cost of such programs. All the studies which contributed data to this review are observational, which downgraded the body of evidence from high to low before even considering other factors which affect the certainty about the direction and size of the effect of intervention on the outcomes. However, it is unlikely to conduct trials examining an intervention such as PCC because it is unethical to randomize diabetic women to receive or not to receive PCC. The only trial included in this review had major biases because it allowed participants to shift between the intervention and the control groups, hence the results lacked internal validity.

### Implication to practice {#sec030}

New strategies for incorporating PCC in ongoing healthcare services, such as adults' diabetic clinics and primary healthcare may prove to be cost effective and improve the feasibility and applicability of PCC globally.

Incorporation of health education about contraception, fertility of women with diabetes, and the importance of pregnancy planning in the services of diabetic clinics may improve the uptake of PCC.

### Implication to research {#sec031}

Further research in interventions for improving pregnancy planning and increase utilization of PCC in different communities may improve our understanding of the poor utilization of PCC and suggest areas for improvement. In addition, research to investigate important outcomes, which are still surrounded by uncertainty, such as the association between PCC and maternal hypoglycemia, should be encouraged. There is lack of studies addressing these problems in low-income countries that raise the need for future research both quantitative and qualitative.

Conclusion {#sec032}
==========

PCC for women with pre-gestational type 1 or type 2 diabetes mellitus is effective in improving rates of congenital malformations. In addition, it may improve the risk of preterm delivery and admission to NICU. PCC probably reduces maternal HbA1C in the first trimester of pregnancy, perinatal mortality and SGA. There is uncertainty regarding the effects of PCC on early booking for antenatal care or maternal hypoglycemia during the first trimester of pregnancy. PCC has little or no effect on other maternal and perinatal outcomes.

Supporting information {#sec033}
======================

###### PRISMA 2009 checklist PCC.

(DOC)

###### 

Click here for additional data file.

###### Search strategy.

(DOCX)

###### 

Click here for additional data file.

###### Excluded studies.

(DOCX)

###### 

Click here for additional data file.

###### Sensitivity analysis.

(DOCX)

###### 

Click here for additional data file.

###### Forest plots.

(DOCX)

###### 

Click here for additional data file.

We would like to thank Roaa Elkouny and A'alaa Abdelrahman for proof editing the final version of the manuscript.

10.1371/journal.pone.0237571.r001

Decision Letter 0

Simeoni

Umberto

Academic Editor

© 2020 Umberto Simeoni

2020

Umberto Simeoni

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

29 Jan 2020

PONE-D-19-30647

Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and fetal outcomes

PLOS ONE

Dear Dr. Fayed,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Would you choose to submit a revised manuscript, please address all the comments made by the reviewers.

 

We would appreciate receiving your revised manuscript by Mar 14 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Umberto Simeoni

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (<http://learn.aje.com/plos/>) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website ([www.editage.com](http://www.editage.com)) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscriptA copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a \*supporting information\* file)A clean copy of the edited manuscript (uploaded as the new \*manuscript\* file)

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Dr Amel Fayed (corresponding author) and co-workers have conducted a systematic review and meta-analysis of the effect of pre-pregnancy care (pre-conception care, PCC) for women with diabetes on maternal and fetal outcomes. The rationale for the study is that since last review also conducted by the first author (dr Wahabi) new studies have been published and a tool for assessing the quality of evidence of outcomes in studies has come into use, the Grading of Recommendations, Assessment, Development and Evaluation (GRADE).

In addition to and to explain my comments to authors above I have some questions and suggestions to the authors, specifically, on the Result section.

Title.

I suggest that the same words are used in the title as in the manuscript i.e. pre-conception care. Not only complications in fetuses are studied but also complications in the newborn, maybe offspring or infants would be more appropriate words.

Abstract.

I suggest that the results in the abstract should be re-evaluated, please see below my comments on the result in the main text. Could you also give the number of women with type 1 and type 2 diabetes included in the studies?

Introduction.

The authors describe the importance of well-regulated glucose levels in pregnant women with diabetes, especially during the first trimester. Further, they state that management of diabetes is a challenge in low- and middle-income countries. Here the burden of diabetes is higher in the younger population thus increasing the risk of complications during pregnancy and in the fetus and newborn child. The variation of uptake of recommendations in different socioeconomic strata in all countries is also problematic. These are important issues, but the current study does not specifically address them as the review includes studies from high-income countries. The reasons for lack of knowledge of how to manage diabetes in low resource and socioeconomic under-privileged regions and what to do to amend this should be addressed in the Discussion.

Methods.

The description of search methods, study selection and identification, and data extraction are well described. Under subheading Quality Assessment the score using stars should be described. What does the stars stand for in the different domains? Describe this process in more detail. In Table 4 for stars are used for bias assessment and their use should be explained as this assessment is crucial for the results of the meta-analyses. Reference \#20 is wrong (line 193), it should be \#21. Line 195; the word trials is misleading as the current literature review only comprise one trial, all other studies are observational.

Assessment of the quality of the evidence (page 9). This section should be thoroughly revised. The symbols of the GRADE tool (used in table 6) should be described and how the design of a study gives the study a default grade should be explained. For instance all observational studies are not default of low quality of evidence. Well-performed cohort studies have usually moderate quality of evidence. Further, reasons for down and up-grading the quality should be summarized, preferably in a supplementary table. Up-grading could also be done if there is a dose-response effect not only if the effect of intervention is great. Albeit, upgrading should be used with care.

Some details: line 212 the table Summary of findings in the manuscript should be referred to.

The statistical analysis is performed with statistical well-known tools and seems appropriate.

Results.

The numbers of full text article is not the same in the text (n=75) and in Figure 1 (n=76) the same applies to excluded studies n=35 and n=36 respectively, please check and revise.

Also check the numbers in table 1. Two studies in the table are not mentioned in the text (20 and 31). Line 261: "..16 were retrospective studies.." but the number within brackets is 17. Under subheading Interventions the references in the text are not congruent with those in table 1. The same apply to the references in the text with subheading Outcome measures. In the table two connected studies are presented as one which is confusing. It would be easier for the reader to check the literature if the articles in the table are presented consecutively according to their reference number.

Subheading "Effects of intervention".

Lines 5-8. Gestational age at booking for antenatal care. The statement on quality of evidence is not supported by the data, albeit the effect of PCC is small. Five studies is not a small number of studies and the number of individuals included is large and the risk of bias as stated by the authors is moderate according to table 6, this should be congruent with the text. The number of studies, if more than one, is not a reason for down-grading of evidence. I suggest your conclusion of very low-quality of evidence should be reconsidered. Figure 2: the green symbol of reference Rosenn 1991 should be explained in the Table text (large drop-out, 50%). Usually studies with a drop-out over 20% are excluded from analysis. Reconsider if this study should be excluded from the analysis? The same applies for Rosenn in Figure 4.

Lines 12-17. Congenital malformation. One study should be excluded from the Forrest plot since it does not contribute to the result (Dunne 1999). Also an analysis excluding studies with high risk for bias should be performed in order to investigate the impact on the outcome, see also Discussion, line 117-121. Please also check the congruence of numbers in text and table.

Line 21-28. HbA1c. The conclusion of high-quality of evidence is not supported by Table 6 where the outcome is designated moderate quality of evidence.

Lines 32-35. Maternal hypoglycemia. All three studies in the meta-analysis are assessed by the authors having low risk of bias. Reconsider the conclusion of very low-quality of evidence. In Figure 5 the text on x-axis (experimental and control) should be replaced to PCC and non-PCC.

Lines 39-42. Preterm delivery. The authors state that the outcome has moderate-quality of evidence due to small effect. The reason for small effect could be that this is actually the true outcome. Small effect size is not conferring down-grading of evidence as is the opposite (large effect could increase the quality of evidence). All included studies (except Dunne 1999) have low risk of bias (the most important weight for assessment of evidence as stated on page 34 lines 25-26 in the manuscript and I fully agree with that). The conclusion should be reconsidered. In the Discussion the global burden of preterm delivery is discussed, the limitation of this review is that the studies are from high-income countries. There is a lack of studies from under-privileged countries where PCC could have a greater impact on this outcome.

Lines 46-50. Perinatal mortality. Similarly, to "preterm delivery". The quality of evidence is not only affected by the effect size (here presumed to increase it) but relies on the quality of the included studies. The reduced risk of perinatal mortality is mainly driven by two older studies Boulot 2003 (low-risk of bias) and Willhoite 1993 (high risk of bias due to differences in baseline characteristics for instance duration of diabetes and difference in prenatal care in the two groups). I suggest that Willhoite and Dunne 1999 is excluded from analysis because of the high risk of bias for those studies. The data should be re-analyzed.

Lines 56-58. Small for gestational age. The included 6 studies have all (except Dunne 1999) low risk of bias and a large number of participants. Reconsider the conclusion of low quality evidence according to my comments to the preceding analyses of preterm delivery and SGA.

Lines 62-65. NICU admission. Low risk of bias for three studies including a large number of participant. Reconsider the conclusion.

Line 69-75. Other outcomes. Many of these outcomes are based on studies with low risk of bias (only shoulder dystocia has low precision (due to low number of events). Some analyses point towards no effect of PCC on outcome with a high quality of evidence. Reconsider the results.

Publication bias. I don't understand how heterogeneity in outcome can explain publication bias in reporting of HbA1c. Can you explain this further?

Can you present data on the number of patients with type 1 and type 2 diabetes in the studies? Were there differences in outcome of PCC in the two conditions?

Discussion.

The authors state that PCC has an impact on several outcomes concerning the mother and the off-spring. The impact might be less or even non-existent in other outcomes should also be reported. The evidence for no difference between intervention and no intervention could be of sufficient quality (for instance if large studies were included in the analysis). This might be very valuable knowledge for maternity health care planners.

Line 117. The authors state that the high quality of evidence on PCC and congenital malformation is mainly based on the large effect size. The upgrading of evidence due to effect size should be used with great caution. The high risk of bias in nearly half of the studies should also be a caveat making the meta-analysis more uncertain, see also my comments to this outcome in the Result section. Still, moderate quality of evidence could be good enough for introduction of an intervention and a greater size of effect have a role for this decision.

Line 122-136. One reason for the lower risk of congenital malformation is better control of blood glucose during pregnancy. Other studies (78-81) have shown a dose-response effect of HbA1c level on congenital malformations, did the authors find dose-response effects in the current study? If this was the case an upgrading of the quality of evidence could be considered.

The authors point to a very important issue in studies with a great time span. Practice changes over time (i.e. different criteria for diabetes diagnosis, and introduction of continuous glucose measurements) and this could be a reason for excluding older studies or perform analyses of studies from different time intervals. A more comprehensive care of women in fertile ages and in pregnant women with diabetes could also diminish the positive effect of specific PCC programs. The effect of PCC could also vary in areas with different socioeconomic status and between high, middle and low income countries which also the authors state in lines 196-198. This issues could be further elaborated in the sections of implications for practice and research, lines 231-246 and joined with the text from lines 208-211.

Lines 157-169. I don't agree that there were a small number of studies supporting the effect of PCC on SGA. See my comments in the Result section.

Line 179-181. Can you explain what you mean with the true effect and how it would be substantially different? In what way? See also my comments to this outcome in the Result section.

The result of this review is rather clear. PCC increases the health of mothers with diabetes and their off-spring in high-income countries. A limitation that leaves gaps of knowledge is that studies from middle and low-income countries were lacking. This is especially important as the authors focus on these issues in the Introduction of the manuscript. The authors describe some studies using surveys and qualitative design to investigate women's attitudes towards pregnancy planning in Britain and the US and one study of risk factors for SGA in Brazil. The results from these studies might help formulate strategies to reach women with diabetes in childbearing age at risk, in underprivileged areas, and in middle and low-income countries.

References.

The references should be scrutinized for typos and incompleteness. For instance \#20, \#23, \#47, \#81.

General remarks.

A linguistic revision of the text is needed and there are many typos and lack of spaces in the text.

Reviewer \#2: The large amount of observations makes it a little difficult to follow the statistical procedures. Trying to calculate some figures, I find the total number of participants in the cohort studies to be 8361, in the article given as 8324 (p. 10, l. 262).

Data for some participants are missing. I found data from 8040 participants possible for meta-analysis, in the paper the number is 8026 (p. 34, l. 3).

Similarly, I calculated the number of subjects studied for HbA1c to be 4907, in the paper given as 4927.

I think the authors are right in their calculations. The results will probably be unchanged.

Have I misunderstood some details on pp. 34-37 (effects of intervention)?

Congenital malformation - text: 24 studies, 5856 women, Table 5: 25 studies, 5903 women

Perinatal mortality - text: ten studies, 3071 women, Table 5: 9 studies, 3024 women

A few remarks on writing:

p\. 8, l. 189 and l. 190 - should probably read \"low risk of bias\" and \"high risk of bias\", respectively, instead of parentheses. Also: - at least one STAR instead of start.

p.8, l. 204 - represents the SLANDERED error \... should probably read STANDARD error?

p\. 9, l. 225 - we assessED the quality \...

p\. 11, l. 264 - and 180 women in the trial, going through 270 pregnancies (it seems that the calculations involve pregnancies and not women?)

p\. 17, regarding study 14/Gunton (45) What does \"Total N= of women: 61\" mean?

and regarding study 15/Gunton (45) - \"Total Number of women:31\"?

p\. 40, l. 101 - slightly earliER booking

l\. 121 - participants were FROM studies \...

p\. 41, l. 131 -27% of participants were FROM studies \...

l\. 154 - were FROM one study \...

p\. 42, l. 168 - participants were FROM one study \...

l\. 177 - the participants were FROM two studies \...

p\. 43, L. 197 - LMICs should probably be defined, although many readers would know the abbreviation (Low and Middle Income Countries?)

Regarding health economics, the different costs might all be given in the same currency, for comparison.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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Author response to Decision Letter 0

10 Mar 2020

Dear Editors,

We would like to thank the reviewers for their informative and constructive comments, based on their directions, we considered their comments and revised all reported assessments numbers and figures.

Kindly find below our point-by-point reply for their comments:

Reviewer 1

We thank the reviewer for his/her meticulous revision of all the outcomes, in some instances we agreed with some of his/her comments and changed our assessment of the GRADE of evidence on certain outcomes. However, we need to explain that the GRADE tool is mainly used to give the policy makers and those who implement evidence some direction about the expected degree of success in improving the particular outcome if the intervention is implemented. Hence, the importance of the effect size, heterogeneity, CI crossing no effect line and the consistency of the direction of outcomes in all the studies and not only the methodological quality of evidence including bias. Another important consideration in our assessment is that all observational studies, based on the GRADE approach (not our decision), start at a score of (low), which is the third in a four-point scale assessing our certainty on the evidence

Reviewer 1 comments Action/comments

Title.

I suggest that the same words are used in the title as in the manuscript i.e. pre-conception care. Not only complications in fetuses are studied but also complications in the newborn, maybe offspring or infants would be more appropriate words. Reply: According to WHO, the perinatal period commences at 22 completed weeks (154 days) of gestation and ends seven completed days after birth which includes all the events reported in the current study. So we changed the term "fetal" to Perinatal" in the title.

Abstract.

I suggest that the results in the abstract should be re-evaluated, please see below my comments on the result in the main text. Could you also give the number of women with type 1 and type 2 diabetes included in the studies?

Reply: Some of the results have been modified according to the reviewer's comments (please see reply to reviewer in results section). We could not find the exact number of women with type 1 and type II diabetes because some studies didn't specify the numbers in each group, most probably because the effect of PCC does change with the type of diabetes unless there were vascular complications related to diabetes and those we have considered when we assessed the presence of confounders in our assessment of bias in the included studies (please see table 4).

.

The authors describe the importance of well-regulated glucose levels in pregnant women with diabetes, especially during the first trimester. Further, they state that management of diabetes is a challenge in low- and middle-income countries. Here the burden of diabetes is higher in the younger population thus increasing the risk of complications during pregnancy and in the fetus and newborn child. The variation of uptake of recommendations in different socioeconomic strata in all countries is also problematic. These are important issues, but the current study does not specifically address them as the review includes studies from high-income countries. The reasons for lack of knowledge of how to manage diabetes in low resource and socioeconomic under-privileged regions and what to do to amend this should be addressed in the discussion.

Reply: We included this information in the in introduction to portray a complete picture about the epidemiology od diabetes is a common health problem all over the world especially young age group and in different countries, hence, the importance of this review to introduce PCC as a preventive measure to most of the complications of diabetes in pregnancy. Further details were included in the discussion

Methods:

The description of search methods, study selection and identification, and data extraction are well described. Under subheading Quality Assessment the score using stars should be described. What does the stars stand for in the different domains? Describe this process in more detail.

Reply: the details of the tool (The Newcastle-Ottawa Scale), has been explained in details in the methods section with its cited reference. (page 8, lines 186-193)

In Table 4 for stars are used for bias assessment and their use should be explained as this assessment is crucial for the results of the meta-analyses. Reply: the details of staring studies was explained in details in the methods section with its cited reference. (page 8, lines 186-193)

Reference \#20 is wrong (line 193), it should be \#21. Corrected

Line 195; the word trials is misleading as the current literature review only comprise one trial, all other studies are observational.

Corrected to studies

Assessment of the quality of the evidence (page 9). This section should be thoroughly revised. The symbols of the GRADE tool (used in table 6) should be described and how the design of a study gives the study a default grade should be explained. For instance, all observational studies are not default of low quality of evidence. Well-performed cohort studies have usually moderate quality of evidence. Further, reasons for down and up-grading the quality should be summarized, preferably in a supplementary table. Up-grading could also be done if there is a dose-response effect not only if the effect of intervention is great. Albeit, upgrading should be used with care.

Some details: line 212 the table Summary of findings in the manuscript should be referred to. The statistical analysis is performed with statistical well-known tools and seems appropriate. Reply: All the details of the GRADE approach are addressed clearly in the methods section according to reference 21.

Kindly find this reference for more explanation and clarifications of the GRADE approach. <https://www.jclinepi.com/article/S0895-4356>(13)00057-7/fulltext

Please refer to the explanations at the top of the reply to reviewers

The numbers of full text article is not the same in the text (n=75) and in Figure 1 (n=76) the same applies to excluded studies n=35 and n=36 respectively, please check and revise. Revised and corrected

Also check the numbers in table 1. Two studies in the table are not mentioned in the text (20 and 31).

All studies mentioned in the table and text were revised and matched for all outcomes

Line 261: "..16 were retrospective studies.." but the number within brackets is 17 All studies mentioned in the table and text were revised and matched for all outcomes

Under subheading Interventions the references in the text are not congruent with those in table 1 All studies mentioned in the table and text were revised and matched for all outcomes

The same apply to the references in the text with subheading Outcome measures. All studies mentioned in the table and text were revised and matched for all outcomes

In the table two connected studies are presented as one which is confusing. It would be easier for the reader to check the literature if the articles in the table are presented consecutively according to their reference number. Unfortunately, this is nor possible because some authors (e,g. Temple ) has more than one publication in two different medical journals but are different outcomes for the same cohort. For the reader to refer to the certain study they have to find the correct citation.

Subheading "Effects of intervention".

Lines 5-8. Gestational age at booking for antenatal care. The statement on quality of evidence is not supported by the data, albeit the effect of PCC is small. Five studies are not a small number of studies and the number of individuals included is large and the risk of bias as stated by the authors is moderate according to table 6, this should be congruent with the text. The number of studies, if more than one, is not a reason for down-grading of evidence. I suggest your conclusion of very low-quality of evidence should be reconsidered. Reply: The quality of evidence was downgraded from low-grade (observational study) to very low -grade due to high- risk of bias in the study with the largest weight (Rossen 1991) and high unexplained heterogeneity (table 6).

Figure 2: the green symbol of reference Rosenn 1991 should be explained in the Table text (large drop-out, 50%). Usually studies with a drop-out over 20% are excluded from analysis. Reconsider if this study should be excluded from the analysis? The same applies for Rosenn in Figure 4. Reply: In the protocol, we did not define drop-off of more than 20% to indicate study exclusion. Loss of follow up is appraised in the NOS for assessment of bias.

The green symbol is present in all the studies in this forest plot and it indicates the roughly the (mean). It is more prominent for the Rosenn 1999 because the small confidence interval (-1.39 to -1.21) which masked the arms of the confidence interval (the two ends of the black line).

Lines 12-17. Congenital malformation. One study should be excluded from the Forrest plot since it does not contribute to the result (Dunne 1999). Reply: Dunne 1999 reported the congenital anomalies and they reported no cases of congenital anomalies in the intervention or the control groups as (ZERO) is a number and the number of participants should be included in the denominator of the pooled estimate we included the study in the forest Plot.

Kindly check this reference:

<https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-7-5>

Also an analysis excluding studies with high risk for bias should be performed in order to investigate the impact on the outcome, see also Discussion, line 117-121. Please also check the congruence of numbers in text and table.

Reply: According to our protocol, we did not plan to do sensitivity analysis based on risk of bias as it is considered in the GRADE approach for quality of evidence. Additionally, kindly see below one example of the forest plot of HbA1c where we excluded all high biased studies (10 studies) however, the pooled effect of PCC on the reduction of HbA1c stayed nearly the same.

Line 21-28. HbA1c. The conclusion of high-quality of evidence is not supported by Table 6 where the outcome is designated moderate quality of evidence.

Reply: we considered the number of participants in studies with high risk of bias versus number in studies with low risk. We added the number of participants in explaining GRADE evaluation in each outcome.

Lines 32-35. Maternal hypoglycemia. All three studies in the meta-analysis are assessed by the authors having low risk of bias. Reconsider the conclusion of very low-quality of evidence. Reply: Please consider that we start from low certainty because of observational studies. From the forest plot, there is no consistency (different direction of effect) , large CI (1.07-1.79) which is not precise and high heterogeneity all these factors affected our certainty of evidence to be very low from low. It means that we are uncertain if the PCC if implemented mothers will have hypoglycemia or not !!!

In Figure 5 the text on x-axis (experimental and control) should be replaced to PCC and non-PCC. Reply: Corrected

Lines 39-42. Preterm delivery. The authors state that the outcome has moderate-quality of evidence due to small effect. The reason for small effect could be that this is actually the true outcome. Small effect size is not conferring down-grading of evidence as is the opposite (large effect could increase the quality of evidence). All included studies (except Dunne 1999) have low risk of bias (the most important weight for assessment of evidence as stated on page 34 lines 25-26 in the manuscript and I fully agree with that). The conclusion should be reconsidered. Reply: We have actually upgraded the evidence from low to moderate due to the reasons you have mentioned in your comments, however we could not improve our certainty of the effect more because of the small effect size. The GRADE approach considers the implications to clinical practice which can be extracted from the body of evidence, e.g does the evidence support that if PCC is implemented one should expect that preterm delivery will be reduced? If the effect size is small then the certainty that will definitely result in reduction of pre-term delivery will be lower because other factors (e.g maternal age, parity, socioeconomic factors...) may play a bigger role in reduction of PTD. Hence the moderate quality of evidence

Please see up/downgrading of the quality of evidence is according to guidelines of GRADE.

<https://www.jclinepi.com/article/S0895-4356>(13)00057-7/fulltext

In the Discussion the global burden of preterm delivery is discussed, the limitation of this review is that the studies are from high-income countries. There is a lack of studies from under-privileged countries where PCC could have a greater impact on this outcome.

We have suggested more than one solution for the provision of PCC globally. Please refer to pp 41-42 lines 215-220

Lines 46-50. Perinatal mortality. Similarly, to "preterm delivery". The quality of evidence is not only affected by the effect size (here presumed to increase it) but relies on the quality of the included studies. The reduced risk of perinatal mortality is mainly driven by two older studies Boulot 2003 (low-risk of bias) and Willhoite 1993 (high risk of bias due to differences in baseline characteristics for instance duration of diabetes and difference in prenatal care in the two groups). I suggest that Willhoite and Dunne 1999 is excluded from analysis because of the high risk of bias for those studies. The data should be re-analyzed. Reply: According to our protocol which was published in the, we did not plan to do sensitivity analysis based on risk of bias, based on the fact that risk of bias of the whole body of evidence (all nine studies) is one of five factors considered in the GRADE approach for quality of evidence. Please refer to the above replies for assessment of GRADE OF EVIDENCE

(Downgrading of the quality of evidence is according to guidelines of GRADE.

<https://www.jclinepi.com/article/S0895-4356>(13)00057-7/fulltext

Lines 56-58. Small for gestational age. The included 6 studies have all (except Dunne 1999) low risk of bias and a large number of participants. Reconsider the conclusion of low quality evidence according to my comments to the preceding analyses of preterm delivery and SGA.

Lines 62-65. NICU admission. Low risk of bias for three studies including a large number of participant. Reconsider the conclusion. Reply: Agree, reconsidered please see text

Line 69-75. Other outcomes. Many of these outcomes are based on studies with low risk of bias (only shoulder dystocia has low precision (due to low number of events). Some analyses point towards no effect of PCC on outcome with a high quality of evidence. Reconsider the results.

Reply: Please look at the CIs of all these outcomes which crossed the no effect line (which is 1), which means it may be effective and it may not be effective (irrespective of all other factors of upgrading or down grading of evidence). In addition, all observational studies started from (low) GRADE and the reasons for upgrading have been mentioned in our methodology in p 9, lines 218-223

Publication bias. I don't understand how heterogeneity in outcome can explain publication bias in reporting of HbA1c. Can you explain this further? Reply: Heterogeneity does not give publication bias but when there is marked heterogeneity the funnel plot gives a distribution of the studies similar to publication bias.

Kindly refer to reference 69 Terrine 2005 for further explanation

Can you present data on the number of patients with type 1 and type 2 diabetes in the studies? Were there differences in outcome of PCC in the two conditions? type 1 and type II patients were reported collectively as some studies did not report the outcomes of each group separately.

Discussion.

The authors state that PCC has an impact on several outcomes concerning the mother and the off-spring. The impact might be less or even non-existent in other outcomes should also be reported. The evidence for no difference between intervention and no intervention could be of sufficient quality (for instance if large studies were included in the analysis). This might be very valuable knowledge for maternity health care planners. Reply: All the outcomes were summarized in the first paragraph and then most of them were elaborated furthermore in the discussion. Other outcomes were discussed on P 40 lines 167-172

Line 117. The authors state that the high quality of evidence on PCC and congenital malformation is mainly based on the large effect size. The upgrading of evidence due to effect size should be used with great caution. The high risk of bias in nearly half of the studies should also be a caveat making the meta-analysis more uncertain, see also my comments to this outcome in the Result section. Still, moderate quality of evidence could be good enough for introduction of an intervention and a greater size of effect have a role for this decision.

Reply: revised and explained please refer to the text

Line 122-136. One reason for the lower risk of congenital malformation is better control of blood glucose during pregnancy. Other studies (78-81) have shown a dose-response effect of HbA1c level on congenital malformations, did the authors find dose-response effects in the current study? If this was the case an upgrading of the quality of evidence could be considered.

Reply: these data are not available in the included study to perform this analysis.

The authors point to a very important issue in studies with a great time span. Practice changes over time (i.e. different criteria for diabetes diagnosis, and introduction of continuous glucose measurements) and this could be a reason for excluding older studies or perform analyses of studies from different time intervals. A more comprehensive care of women in fertile ages and in pregnant women with diabetes could also diminish the positive effect of specific PCC programs. The effect of PCC could also vary in areas with different socioeconomic status and between high, middle and low income countries which also the authors state in lines 196-198. This issues could be further elaborated in the sections of implications for practice and research, lines 231-246 and joined with the text from lines 208-211. Reply: in the protocol, sensitivity analysis was planned for unexplained high heterogeneity only, not for bias or temporal reasons

Lines 157-169. I don't agree that there were a small number of studies supporting the effect of PCC on SGA. See my comments in the Result section. Reply: Corrected

Line 179-181. Can you explain what you mean with the true effect and how it would be substantially different? In what way? See also my comments to this outcome in the Result section. Reply: As a sequence of the uncertainty of the available evidence, the true effect can be different from the reported one either in direction or magnitude or both.

The result of this review is rather clear. PCC increases the health of mothers with diabetes and their off-spring in high-income countries. A limitation that leaves gaps of knowledge is that studies from middle and low-income countries were lacking. This is especially important as the authors focus on these issues in the Introduction of the manuscript.

The authors describe some studies using surveys and qualitative design to investigate women's attitudes towards pregnancy planning in Britain and the US and one study of risk factors for SGA in Brazil. The results from these studies might help formulate strategies to reach women with diabetes in childbearing age at risk, in underprivileged areas, and in middle and low-income countries.

We had to discuss this issue in the discussion and not in the introduction because it became apparent after we have done the review

Indeed these studies will be helpful especially if they collectively analyzed in a qualitative review. However we cannot comment on that because we don't know how many studies are available and what their quality are

References.

The references should be scrutinized for typos and incompleteness. For instance, \#20, \#23, \#47, \#81. Reply: corrected

General remarks.

A linguistic revision of the text is needed and there are many typos and lack of spaces in the text. Reply: Corrected

 

Reviewer 2

We thank the reviewer for his/her meticulous review of the number included in the review which was of great help to us

Reviewer 2 comments Action/comments

Trying to calculate some figures, I find the total number of participants in the cohort studies to be 8361, in the article given as 8324 (p. 10, l. 262). Recalculation: PCC:3213, NOPCC: 4986. Total: 8199

• In Gunton(2000): reported a total of 61 women.

24 pregnancies were reported in PCC (some participants had more than one pregnancy) and 69 pregnancies were reported in NO-PCC (some participants had more than one pregnancy)

• Gunton (2002): reported a total of 31 women. 19 pregnancies were reported in PCC (some participants had more than one pregnancy) and 16 pregnancies were reported (some participants had more than one pregnancy

• Kallas-Koeman (2012): Data available for only 71and 150 participants.

Data for some participants are missing. I found data from 8040 participants possible for meta-analysis, in the paper the number is 8026 (p. 34, l. 3). Corrected:

8199 participants

I calculated the number of subjects studied for HbA1c to be 4907, in the paper given as 4927. Recalculated: the correct number is 4927, please see first forest plots which is matching the number in table 1 and in the text

Have I misunderstood some details on pp. 34-37 (effects of intervention)?

Please note that some forest plots are shown in supplementary files (only 8 in the manuscript), all outcomes are listed in the text. Summary of findings table includes only the important outcomes.

Congenital malformations - text: 24 studies, 5856 women, Table 5: 25 studies, 5903 women Revised and Corrected:

: the total number of included studies is 25 with a total of 5903 participants. The number corrected in the text.

Perinatal mortality - text: ten studies, 3071 women, Table 5: 9 studies, 3024 women Revised and corrected:

10 studies with 3071 women

p\. 8, l. 189 and l. 190 - should probably read \"low risk of bias\" and \"high risk of bias\", respectively, instead of parentheses. Also: - at least one STAR instead of start. Revised and corrected:

p.8, l. 204 - represents the SLANDERED error \... should probably read STANDARD error? Revised and corrected:

p\. 9, l. 225 - we assessED the quality \... Revised and corrected:

p\. 11, l. 264 - and 180 women in the trial, going through 270 pregnancies (it seems that the calculations involve pregnancies and not women?) Revised and corrected:

p\. 17, regarding study 14/Gunton (45) What does \"Total N= of women: 61\" mean? Revised and corrected:

• The numbers rewritten and explained in table 1 as following

• In Gunton(2000):

24 pregnancies were reported in PCC (some participants had more than one pregnancy) and 69 pregnancies were reported in NO PCC (some participants had more than one pregnancy)

and regarding study 15/Gunton (45) - \"Total Number of women:31\"? Revised and corrected:

• The numbers rewritten and explained in table 1 as following

• Gunton (2002): reported as Total N= of women: 31 in table 1. 19 pregnancies were reported in PCC (some participants had more than one pregnancy) and 16 pregnancies were reported (some participants had more than one pregnancy

p\. 40, l. 101 - slightly earliER booking Revised and corrected:

l\. 121 - participants were FROM studies \... Revised and corrected:

p\. 41, l. 131 -27% of participants were FROM studies \... Revised and corrected:

l\. 154 - were FROM one study \... Revised and corrected:

p\. 42, l. 168 - participants were FROM one study \... Revised and corrected:

l\. 177 - the participants were FROM two studies \... Revised and corrected:

p\. 43, L. 197 - LMICs should probably be defined, although many readers would know the abbreviation (Low and Middle Income Countries?)

Regarding health economics, the different costs might all be given in the same currency, for comparison. Revised and corrected:
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Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and Perinatal outcomes

PLOS ONE

Dear Dr. Fayed,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that the revised manuscript addresses some of the criticisms made by te reviewers, but still major methodological issues are considered unsatisfactory by the reviewers, including the statistical reviewer we have invited. 

The high risk of bias resulting from the selection of studies is still insufficiently assessed and taken into account in the manuscript.

We would be happy to reconsider a final, revised version of the manuscript, could these major drawbacks be fixed by the authors. However, we would also perfectly understand if you chose not to resubmit, being aware of the work in depth needed to meet the criteria of the journal for publication.

Please note that, still, wording and English language errors are persisting in the manuscript.

Please submit your revised manuscript by Jul 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Umberto Simeoni

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you very much for your appreciation of my work with your manuscript.

Dr Amel Fayed (corresponding author) and co-workers have answered to my review and done a lot of changes that are satisfying and thus increased the clarity of the manuscript. Still there are some issues that need to be addressed.

General.

I don't think that we disagree on the great importance that evidence or lack of evidence for effect or lack of effect of different interventions are studied using systematic reviews and meta-analyses. It is crucial to guide health care staff as well other stakeholder in decisions of interventions demanding much resources. Before GRADING the evidence of different outcomes the included studied are assessed for relevance and quality as you have described. In a conservative assessment, which I propose, studies with high drop-out rate (\>30%) and low quality are excluded as the results of these studies are not possible to evaluate. They could be included but then the effect on the outcome must be assessed as the authors have done in presenting the percentage of studies of high risk of bias in the analysis. Observational studies can have very low GRADE score, low GRADE score but some high quality cohort studies can have moderate GRADE score. Thus, the GRADE score does not only depend on the design of the studies but also of their inherent quality. This is very important to recognize in issues that can´t be studied with randomized trials for ethical reasons as in the current systematic review.

Title.

Perinatal is an appropriate word, with lower case p. The word fetal is still used in the manuscript and should be changed for instance in line 135, 314. There might be more, so please scrutinize the manuscript.

Abstract.

Conclusion: I suggest you use the term pre-gestational diabetes as there was no possibility to present the frequencies of typ 1 and type 2, respectively. The assessment of risk of hypoglycemia during first trimester was based on studies of type 1 diabetes, which ought to be pointed out in the manuscript. This lack of information in the rest of literature should be addressed in the manuscript for instance in the section on page 10 under the heading: Participants (line 266).

I can´t see any description of confounders such as other cardiovascular conditions (hypertension, lipid disturbances and obesity) in Table 4 as referred to by the authors.

Introduction.

The authors describe the variation of uptake of recommendations in different socioeconomic strata. In case "Low resource countries" are equivalent to "low income countries" use the latter term throughout the manuscript. If not define what you mean by low resource country. These are important issues the in the Discussion the authors should elaborate what to do to amend this. As there is a lack of studies addressing these problems it have implications for future research both quantitative and qualitative and this should be pointed out under subheading "Implications to research" (line 251).

Methods.

Under subheading Quality Assessment the score using stars is still not described neither in the text nor in the text accompanying Table 4. Further, assessment of the quality of the evidence and the symbols of the GRADE tool should be described, preferably in a supplementary table. I don't think it is enough to refer to other publications.

Results.

The two connected studies (e.g. Temple) presented as one as they describe different outcomes in the same populations ought to be presented separately as the result are different outcomes if the authors want to make it easier for the reader to check the literature. The same applies if the articles in the table are presented consecutively according to their reference number.

Subheading "Effects of intervention".

Gestational age at booking for antenatal care. I am satisfied that you omitted the statement of small number of studies. All symbol or acronyms used in a table (or a figure) such as the green dot should be explained in the explaining text or legend, in this case: green dot, calculated mean.

Congenital malformation, I accept your explanation. Line 21 change "form" to "from".

Line 28 change "form" to "from".

Maternal hypoglycemia. All three studies in the meta-analysis are assessed by the authors as having low risk of bias which means that they are of high quality although they have low numbers of events. This could increase the risk of bias. More importantly, the oldest (Steel et al) was published 1990 with data from the nineteen seventies and eighties before the meticulous surveillance of b-glucose and new recombinant, ultra-rapid acting insulins were introduced in contrast to Holmes et al. published 2017 and Temple et al who used data from 1990 to 2002. The heterogeneity could thus be caused by secular trends in treatment and surveillance. The 2 modern studies (Holmes and Temple) show no significant difference between PCC and controls. This implicates that maternal hypoglycemia in modern management of type 1 diabetic women (at least in high income countries) is not influenced by PCC. If the authors still consider Holmes and Temple having low risk of bias, I think that the evidence for this outcome should be low-quality, not very-low quality. I would say that you are not totally uncertain if PPC confers hypoglycemia or not compared to non-PCC, but it might not matter, still more studies could alter the evidence.

I think your explanation of the result concerning HbA1c applies here. The explanation of few studies shall be omitted from the text. I presume that your statement of true effect means that using modern data and more research would show if the risk of hypoglycemia is increased or decreased using PCC in a time with continuous glucose measuring (CGM) for an increasing part of patients with type 1 diabetes. You have already mentioned this in implications for research.

Preterm delivery. Omit the sentence "The grade of evidence is considered moderate due to the small effect". A small effect could be the true outcome. Adjust sentence in lines 52-53 ...selective reporting increase our confidence in the outcome of a small reduction (4%) in preterm delivery.

Perinatal mortality. The upgrading is a too high. A reduction of RR to \< 0.5 as in the current meta-analysis increase the grade by one star to moderate quality of evidence. RR \< 0.2, which is not the case here, gives rise to two stars. The quality of evidence should thus be moderate.

Small for gestational age. The RR is 0.52 not reaching the level \<0.50 for upgrading one star. Thus up-grading is not an obvious action. If most included studies have low risk of bias the default grade score could be moderate quality. Upgrading to high is not appropriate here.

Other outcomes. Many of these outcomes are based on studies with low risk of bias. As the authors point out in the reply the CI of most studies cross the line depicting no significant difference between the PCC and non-PCC groups, which means that PCC might have no effect on these outcomes. Many studies with low bias and no difference between groups could render an upgrading, but I can accept your statement of low-certainty evidence.

Discussion.

The impact of PCC might be less or even non-existent in some outcomes. This should be summarized in the first paragraph as it is valuable knowledge for maternity health care planners. The risk for hypoglycemia should be elaborated further as one of the included studies describes management no longer used in high income countries.

Lines 142- 143. Alter to ... "moderate quality albeit the effect was size was small".

The authors point to a very important issue in studies with a great time span. Practice changes over time (i.e. different criteria for diabetes diagnosis, and introduction of continuous glucose measurements) this is especially important for the risk of hypoglycemia during pregnancy, which was much discussed earlier when stricter management began. I persists in the suggestion that you address this, even if you do no sensitivity analysis as this an important outcome that might need further studies with modern treatment. This should be addressed in connection to the last paragraph on page 40, lines 193-195. See also my comments in the result section.

The result of this review is rather clear. PCC increases the health of mothers with diabetes and perinatal period of the off-spring in high-income countries. The authors describe some studies using surveys and qualitative design to investigate women's attitudes towards pregnancy planning in Britain and the US and one study of risk factors for SGA in Brazil. The results from these studies might help formulate strategies to reach women with diabetes in childbearing age at risk, in underprivileged areas, and in low-income countries. This could be addressed in the section implications for research.

General remarks.

A further linguistic revision of the text is needed and there are still typos in the text.

Reviewer \#2: With the large amount of data, the authors should check carefully the numbers in text and tables.

Abstract

The effect on maternal hypoglycemia is reported to be RR 1,42;95% CI: 0,72-2,82 (p 2, l 60) and also in the Effects of intervention (p 32, l 36), while in Tables 5 and 6 it is said to be RR 1,38; 95% CI 1,07-1,79.

Search methods

..all the literature published up to March 2019 ..

This sentence might have included \"between 1983 and ..\" - this information is given in Study Characteristics (p 10, l 268)., One study dated 1982 is also included, maybe this one was found linked to another study?

Table 1

Cohort study 12 (Garcia-Patterson): a miscarriage rate of 13/66 gives 53 continuing pregnancies. The rate of SGA should probably read 1/53.

Similarly, the rate of RDS should probably read 12/119.

Table 2

Macrosomia rate in the NO-PCC group should probably read 4/12.

Assessment of the methodological quality of the included studies

Ref (40) is named Rosen et al (p 26, l 327). The correct spelling is Rosenn, as given in References, Tables 1 and 4.

Effects of intervention

Here the same reference is named Rossen (p 31, l 9).

Gestational age at booking for antenatal care

MD 1,31(probably weeks? as it is translated into approximately ten days) - p 31, l 7.

Discussion

Incremental increase \... (p 38, l 134) is superfluous.

FORM should be corrected to FROM at several places (p 31, l 21, p 32, l 28 and 51, p 33, l 73)

Reviewer \#3: Conduct a meta-analysis to evaluate the effectiveness and safety of pre-conception care in improving maternal and perinatal outcomes and evaluate the grade of the body of evidence for each outcome. They identify 36 studies and the meta-analysis results showed that PCC results in large reduction in congenital malformations, lowers HaA1c in the first trimester of pregnancy, lowers the preterm delivery rate

1\. Abstract: "the result... that PCC results in large reduction in congenital malformations, ...owers HbA1c...." the causal effect was implied in the results. However, the study includes both trial and observational studies. The causal effect should be avoided throughout the manuscript.

2\. Line 311. 21 studies were assigned to be at low risk of bias while 15 studies at high risk of bias. A sensitive analysis may be warranted to evaluate the robustness of the findings.

3\. Figures 2 and 9. What's the green rectangle in the figure 2 or blue rectangle in figure 9? Explanation to the figures are needed.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237571.r004

Author response to Decision Letter 1

19 Jun 2020

Dear Editor and reviewers,

We would like to thank our reviewers for their constructive comments. We agreed with our reviewers on their feedback and all required changes were done accordingly.

Point-by-point reply:

Reviewer \#1: Thank you very much for your appreciation of my work with your manuscript.

Dr Amel Fayed (corresponding author) and co-workers have answered to my review and done a lot of changes that are satisfying and thus increased the clarity of the manuscript. Still there are some issues that need to be addressed.

General.

I don't think that we disagree on the great importance that evidence or lack of evidence for effect or lack of effect of different interventions are studied using systematic reviews and meta-analyses. It is crucial to guide health care staff as well other stakeholder in decisions of interventions demanding much resources. Before GRADING the evidence of different outcomes, the included studied are assessed for relevance and quality as you have described. In a conservative assessment, which I propose, studies with high drop-out rate (\>30%) and low quality are excluded as the results of these studies are not possible to evaluate. They could be included but then the effect on the outcome must be assessed as the authors have done in presenting the percentage of studies of high risk of bias in the analysis. Observational studies can have very low-grade score, low GRADE score but some high-quality cohort studies can have moderate GRADE score. Thus, the GRADE score does not only depend on the design of the studies but also of their inherent quality. This is very important to recognize in issues that can´t be studied with randomized trials for ethical reasons as in the current systematic review.

Reply: We totally agree with the reviewer and we have conducted sensitivity analysis excluding high risk of bias studies from the analysis to confirm the statement. Please see page (35,36, supplement 4)

Title.

• Perinatal is an appropriate word, with lower case p. The word fetal is still used in the manuscript and should be changed for instance in line 135, 314. There might be more, so please scrutinize the manuscript.

Reply: Agree and Done

Abstract.

Conclusion: I suggest you use the term pre-gestational diabetes as there was no possibility to present the frequencies of typ 1 and type 2, respectively. The assessment of risk of hypoglycemia during first trimester was based on studies of type 1 diabetes, which ought to be pointed out in the manuscript. This lack of information in the rest of literature should be addressed in the manuscript for instance in the section on page 10 under the heading: Participants (line 266).

I can´t see any description of confounders such as other cardiovascular conditions (hypertension, lipid disturbances and obesity) in Table 4 as referred to by the authors.

Reply: Agree done as below

• Pregestational diabetes was used,

• (all reported results among type 1 diabetes) was added in the assessment of maternal hypoglycemia (page 12, line 310-311)

• "Most of studies did not report the differences in the outcomes among type 1 versus type 2 diabetes, as a result, we could not conduct the analysis separately for each type of diabetes" added to participants section, page 11, lines 285,286

Introduction.

The authors describe the variation of uptake of recommendations in different socioeconomic strata. In case "Low resource countries" are equivalent to "low income countries" use the latter term throughout the manuscript. If not define what you mean by low resource country. These are important issues the in the Discussion the authors should elaborate what to do to amend this. As there is a lack of studies addressing these problems it have implications for future research both quantitative and qualitative and this should be pointed out under subheading "Implications to research" (line 251).

Reply: Reply: Agree done as below

• "Low income countries" was used instead of low resource countries.

• There is lack of studies addressing these problems in the low-income countries that raise the need for future research both quantitative and qualitative, added to implication to research section, page 45, lines 244-246

Methods.

Under subheading Quality Assessment the score using stars is still not described neither in the text nor in the text accompanying Table 4. Further, assessment of the quality of the evidence and the symbols of the GRADE tool should be described, preferably in a supplementary table. I don't think it is enough to refer to other publications.

Reply: Reply: Agree done as below

• This paragraph was added to the methods section (page 8, lines 224-250)

"The criteria assessed were: participants' selection, comparability of groups and assessment of outcome for cohort studies. Participants' selection, comparability of groups, and exposure criteria were used to assess the case-control studies. The maximum number of stars is nine: four stars awarded for selection-selection of exposed and non- exposed, ascertainment of exposure and temporal relation between exposure and outcome-, two for comparability if analysis controlled for confounder- and three stars awarded for outcome if the length of follow up was adequate, no attrition bias, and outcome was assessed independent of exposure Studies at "high risk of bias" score less than six stars or scores no stars in comparability domain irrespective of the number of stars scored."

• This caption was added to table 4:

"Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). The number of stars represents the risk of bias, the maximum number of stars is nine, studies were classified as "low risk of bias" if they received a score of six stars or more and there is at least one star in the comparability domain. Studies at "high risk of bias" score less than six stars or scores no stars in comparability domain irrespective of the number of stars scored"

• This caption was added to the GRADE table

a Upgraded to high because of large effect size, consistency of direction of effect, no indirectness of evidence, and no heterogeneity or publication bias.

b Upgraded to moderate due to the narrow confidence intervals, consistency of direction of effect, no indirectness of evidence, and low risk of bias, no heterogeneity or publication bias.

c Downgraded to very low-grade due to the high risk of bias in the study with the largest weight (Rosenn 1991) and high unexplained heterogeneity

d Upgraded to moderate-certainty level because of low bias (77% of the participants were from studies at low risk of bias), while heterogeneity can be explained by long span of time between the first and the last study (1982 and 2017), The publication bias can be explained with the heterogeneity.

e Downgraded to very low-level certainty because of small number of studies, low bias, explained heterogeneity

f Upgraded to moderate-certainty level because of narrow confidence intervals, consistency of direction of effect, no indirectness of evidence, low risk of bias, low heterogeneity, no evidence of selective reporting.

G Upgraded to moderate-certainty level because the large effect size with precise narrow confidence interval, consistency of direction of effect, no indirectness of evidence, and no heterogeneity and no evidence of selective reporting.

Results.

The two connected studies (e.g. Temple) presented as one as they describe different outcomes in the same populations ought to be presented separately as the result are different outcomes if the authors want to make it easier for the reader to check the literature. The same applies if the articles in the table are presented consecutively according to their reference number.

Reply: Done

References are cited in order at first mention in the table of included studies, studies are ordered in an alphabetical order to make it easier to list. Results are reported from different studies separately as in (Temple a,b) cited as two different references.

Subheading "Effects of intervention". However, it is not possible to reference them as one article as they were published in separate journals.

Gestational age at booking for antenatal care. I am satisfied that you omitted the statement of small number of studies. All symbol or acronyms used in a table (or a figure) such as the green dot should be explained in the explaining text or legend, in this case: green dot, calculated mean.

Reply: Done

Captions for all figures were updated

Congenital malformation, I accept your explanation. Line 21 change "form" to "from".

Reply: Done

Line 28 change "form" to "from".

Reply: Done

Maternal hypoglycemia. All three studies in the meta-analysis are assessed by the authors as having low risk of bias which means that they are of high quality although they have low numbers of events. This could increase the risk of bias. More importantly, the oldest (Steel et al) was published 1990 with data from the nineteen seventies and eighties before the meticulous surveillance of b-glucose and new recombinant, ultra-rapid acting insulins were introduced in contrast to Holmes et al. published 2017 and Temple et al who used data from 1990 to 2002. The heterogeneity could thus be caused by secular trends in treatment and surveillance. The 2 modern studies (Holmes and Temple) show no significant difference between PCC and controls. This implicates that maternal hypoglycemia in modern management of type 1 diabetic women (at least in high income countries) is not influenced by PCC. If the authors still consider Holmes and Temple having low risk of bias, I think that the evidence for this outcome should be low-quality, not very-low quality. I would say that you are not totally uncertain if PPC confers hypoglycemia or not compared to non-PCC, but it might not matter, still more studies could alter the evidence.

Reply: Done, we agree with the reviewer that more studies are needed to improve certainty

I think your explanation of the result concerning HbA1c applies here. The explanation of few studies shall be omitted from the text. I presume that your statement of true effect means that using modern data and more research would show if the risk of hypoglycemia is increased or decreased using PCC in a time with continuous glucose measuring (CGM) for an increasing part of patients with type 1 diabetes. You have already mentioned this in implications for research.

Reply: agree

Preterm delivery. Omit the sentence "The grade of evidence is considered moderate due to the small effect". A small effect could be the true outcome. Adjust sentence in lines 52-53 ...selective reporting increase our confidence in the outcome of a small reduction (4%) in preterm delivery.

Reply: Done

The sentence was omitted and the second sentence was adjusted.

Perinatal mortality. The upgrading is a too high. A reduction of RR to \< 0.5 as in the current meta-analysis increase the grade by one star to moderate quality of evidence. RR \< 0.2, which is not the case here, gives rise to two stars. The quality of evidence should thus be moderate.

Reply: Corrected in abstract, results and discussion

Small for gestational age. The RR is 0.52 not reaching the level \<0.50 for upgrading one star. Thus up-grading is not an obvious action. If most included studies have low risk of bias the default grade score could be moderate quality. Upgrading to high is not appropriate here.

Reply: Corrected in abstract, results and discussion.

Other outcomes. Many of these outcomes are based on studies with low risk of bias. As the authors point out in the reply the CI of most studies cross the line depicting no significant difference between the PCC and non-PCC groups, which means that PCC might have no effect on these outcomes. Many studies with low bias and no difference between groups could render an upgrading, but I can accept your statement of low-certainty evidence.

Reply: Agree

Discussion.

The impact of PCC might be less or even non-existent in some outcomes. This should be summarized in the first paragraph as it is valuable knowledge for maternity health care planners. The risk for hypoglycemia should be elaborated further as one of the included studies describes management no longer used in high income countries.

Lines 142- 143. Alter to ... "moderate quality albeit the effect was size was small".

The authors point to a very important issue in studies with a great time span. Practice changes over time (i.e. different criteria for diabetes diagnosis, and introduction of continuous glucose measurements) this is especially important for the risk of hypoglycemia during pregnancy, which was much discussed earlier when stricter management began. I persists in the suggestion that you address this, even if you do no sensitivity analysis as this an important outcome that might need further studies with modern treatment. This should be addressed in connection to the last paragraph on page 40, lines 193-195. See also my comments in the result section.

Reply: Done

This paragraph was added to the discussion section

Meta-analysis results showed that the effect of PCC on maternal hypoglycemia was of low-certainty level. The three included studies had a low risk of bias but a high level of heterogeneity. Studies included were conducted in different time periods, during which tremendous changes were made with the management of diabetes, which explains the heterogeneity level. Evidence could be altered if more studies were to be carried out.

Sensitivity analysis was added according to level of quality of included studies (supplementary 4)

The result of this review is rather clear. PCC increases the health of mothers with diabetes and perinatal period of the off-spring in high-income countries. The authors describe some studies using surveys and qualitative design to investigate women's attitudes towards pregnancy planning in Britain and the US and one study of risk factors for SGA in Brazil. The results from these studies might help formulate strategies to reach women with diabetes in childbearing age at risk, in underprivileged areas, and in low-income countries. This could be addressed in the section implications for research.

Reply: Done

This paragraph was added to implication to research

There is lack of studies addressing these problems in the low-income countries that raise the need for future research both quantitative and qualitative.

General remarks.

A further linguistic revision of the text is needed and there are still typos in the text.

Reply: Done

Reviewer \#2: With the large amount of data, the authors should check carefully the numbers in text and tables.

Abstract

The effect on maternal hypoglycemia is reported to be RR 1,42;95% CI: 0,72-2,82 (p 2, l 60) and also in the Effects of intervention (p 32, l 36), while in Tables 5 and 6 it is said to be RR 1,38; 95% CI 1,07-1,79.

Reply: Corrected according to the tables

Search methods

..all the literature published up to March 2019 ..

This sentence might have included \"between 1983 and ..\" - this information is given in Study Characteristics (p 10, l 268)., One study dated 1982 is also included, maybe this one was found linked to another study?

Reply: We mean studies from the commencement of each database till March 2019

Table 1

Cohort study 12 (Garcia-Patterson): a miscarriage rate of 13/66 gives 53 continuing pregnancies. The rate of SGA should probably read 1/53.

Similarly, the rate of RDS should probably read 12/119.

Reply: corrected

Table 2

Macrosomia rate in the NO-PCC group should probably read 4/12.

Reply: corrected

Assessment of the methodological quality of the included studies

Ref (40) is named Rosen et al (p 26, l 327). The correct spelling is Rosenn, as given in References, Tables 1 and 4.

Reply Corrected

Effects of intervention

Here the same reference is named Rossen (p 31, l 9).

Reply: Corrected

Gestational age at booking for antenatal care

MD 1,31(probably weeks? as it is translated into approximately ten days) - p 31, l 7.

Reply: Yes, it was computed as weeks in the mata-analysis

Discussion

Incremental increase \... (p 38, l 134) is superfluous.

Reply: Corrected to this sentence

"Many studies confirmed the incremental increase in the rate of adverse pregnancy outcomes with the increase in the level of HbA1c"

FORM should be corrected to FROM at several places (p 31, l 21, p 32, l 28 and 51, p 33, l 73)

Reply: Corrected

Reviewer \#3: Conduct a meta-analysis to evaluate the effectiveness and safety of pre-conception care in improving maternal and perinatal outcomes and evaluate the grade of the body of evidence for each outcome. They identify 36 studies and the meta-analysis results showed that PCC results in large reduction in congenital malformations, lowers HaA1c in the first trimester of pregnancy, lowers the preterm delivery rate

1\. Abstract: "the result... that PCC results in large reduction in congenital malformations, ...owers HbA1c...." the causal effect was implied in the results. However, the study includes both trial and observational studies. The causal effect should be avoided throughout the manuscript.

Reply: revised.

2\. Line 311. 21 studies were assigned to be at low risk of bias while 15 studies at high risk of bias. A sensitive analysis may be warranted to evaluate the robustness of the findings.

Reply: Done

• Sensitivity analysis according to the quality of included studies was done, all forest plots are added to Supplementary file 4, method of sensitivity analysis was added to the methods section and results of sensitivity analysis was added to the results section.

3\. Figures 2 and 9. What's the green rectangle in the figure 2 or blue rectangle in figure 9? Explanation to the figures are needed

Reply: explanation was added to all figures.
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PLOS ONE

Dear Dr. Fayed,

Thank you for submitting your manuscript to PLOS ONE.

We consider that this revised version is considerably improved, although some minor points need to be addressed before it can be accepted, according to reviewer\'s 1 last remarks (below).   

Please submit your reply and final revision of the manuscript by Sep 03 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Umberto Simeoni

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Comments to authors.

Dr Amel Fayed (corresponding author) and co-workers have answered to my review and done a lot of more changes that are satisfying and thus increased the clarity of the manuscript. Still there are some issues that need to be addressed.

Title. Perinatal should be in lower case "perinatal".

Methods.

The caption of the GRADE table.

e\. I don't agree that the number of studies is low. Three studies can be good enough especially if they have low bias. The problem here is that the study with the greatest difference between intervention and control is very old and reflect a surveillance of blood glucose no longer in use. I suggest a wording such as "Downgraded to very low-level of certainty as there was a high heterogeneity due to major changes in surveillance of diabetes between the studies".

Results.

I can´t see that the green dots in the figures are explained. Add an explanation in the captions of all illustrations.

Maternal hypoglycemia.

In table 6, Summary of findings, you state that PCC has no effect on hypoglycemia but in fact the RR is 1.38 (1.07-1.79) a significant difference. So the conclusion is that it seems to have an effect. You explain this finding in the Discussion in a satisfying way. In the text of the result section (page 33, line 36) I suggest that you alter the text to "PCC seems to have an effect on hypoglycemia during the first....) and omit small number of studies and emphasize the great span of time between studies one of which used blood glucose surveillance no longer in use.

Discussion.

I can´t find the sensitivity analysis of maternal hypoglycemia that according to the authors is included in supplement 4.

There are still some typos in the manuscript. For instance an extra dot in row 167, page 41. In table 4 "Risk of bias assessment of the included studies (Steel 1982,1990) right column what is meant? The low risk due to age difference and number of smokers between the groups no regression??

In the text under Table 4 (page 31) Studies at "high risk of bias" score less than six stars or score no stars ...."

You need to scrutinize the manuscript for errors.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237571.r006

Author response to Decision Letter 2

22 Jul 2020

Dear Editor,

We would like to thank our reviewers for their constructive comments, and here are our point-by-point replies:

Title. Perinatal should be in lower case "perinatal".

Reply: Done

Methods.

The caption of the GRADE table.

e\. I don't agree that the number of studies is low. Three studies can be good enough especially if they have low bias. The problem here is that the study with the greatest difference between intervention and control is very old and reflect a surveillance of blood glucose no longer in use. I suggest a wording such as "Downgraded to very low-level of certainty as there was a high heterogeneity due to major changes in surveillance of diabetes between the studies".

Reply: Corrected to high heterogeneity and inconsistency of direction of effect as the point estimate of each study is indifferent place in the forest plot

Results.

I can´t see that the green dots in the figures are explained. Add an explanation in the captions of all illustrations.

Reply: All graphs have explanation as the following

"The large green square represents the estimate effect of the study with the highest weight and very precise 95% CI. The black diamond represents the pooled difference estimate. Heterogeneity is quantified by I2 statistics, an I2 value ≥ 50 indicates substantial heterogeneity. Estimated results are presented as mean difference with 95% Confidence Interval. PCC= Preconception care; No PCC= No preconception care; CI= Confidence intervals."

Maternal hypoglycemia.

In table 6, Summary of findings, you state that PCC has no effect on hypoglycemia but in fact the RR is 1.38 (1.07-1.79) a significant difference. So the conclusion is that it seems to have an effect. You explain this finding in the Discussion in a satisfying way. In the text of the result section (page 33, line 36) I suggest that you alter the text to "PCC seems to have an effect on hypoglycemia during the first....) and omit small number of studies and emphasize the great span of time between studies one of which used blood glucose surveillance no longer in use.

Reply: The paragraph was changed into the following paragraph

"We are uncertain about the effect of PCC on maternal hypoglycemia during the first trimester of pregnancy; (RR 1.38; 95% CI: 1.07- 1.79); three studies; 686 women; very low-certainty evidence) (Fig 5) (table 5). The grade of evidence was downgraded from low to very low due to inconsistency of the direction of effect and high heterogeneity (I2 =76%) in the included studies (table 6). The true effect is likely to be substantially different from the effect estimated in this review."

Discussion.

I can´t find the sensitivity analysis of maternal hypoglycemia that according to the authors is included in supplement 4.

Reply : The three studies included in the assessment of hypoglycemia were all of low-risk of bias and the heterogeneity is explained by the long time span of the included studies, that is why we did not conduct sensitivity analysis for the maternal hypoglycemia outcome because we restricted the sensitivity analysis to outcomes with studies with high risk of bias as you have suggested. However, we decided to exclude the oldest study from the meta-analysis to support our discussion of its effect and not as sensitivity analysis, please see the Forest Plot below (S4 figure 8)

Supplementary Fig 8. Risk ratio for maternal hypoglycemia from three studies of women with pre-existing diabetes mellitus who did or did not receive preconception care.

Data of Steel 1990 were not estimated in the analysis. The large blue square represents the estimate effect of the study with he highest weight and very precise 95% CI. The black diamond represents the pooled risk estimate. Heterogeneity is quantified by I2 statistics, an I2 value ≥ 50 indicates substantial heterogeneity. Estimated results are presented as risk ratio with 95% Confidence Interval. PCC= Preconception care; No PCC= No preconception care; CI= Confidence intervals.

There are still some typos in the manuscript. For instance, an extra dot in row 167, page 41.

Reply: corrected

In table 4 "Risk of bias assessment of the included studies (Steel 1982,1990) right column what is meant? The low risk due to age difference and number of smokers between the groups no regression??

Reply: Corrected

There is no clinical difference between the studied groups regarding the age (27 vs 25), there is difference in other confounders such as number of smokers and no adjustment or regression analysis was done, so this study lost one stars in comparability and considered at "Low risk of bias".

In the text under Table 4 (page 31) Studies at "high risk of bias" score less than six stars or score no stars ...."

Reply: Corrected to

Studies at "high risk of bias" scored less than six stars or scored no stars in the comparability domain, irrespective of the number of stars scored.
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Dear Dr. Fayed,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Umberto Simeoni

Academic Editor

PLOS ONE
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Dear Dr. Fayed:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.
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PLOS ONE Editorial Office Staff

on behalf of

Dr. Umberto Simeoni
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